[P02BB01, trichlorfon, Metrifonate may increase the bradycardic activities of Pindolol.]
[S02DA03, antipyrine, Antipyrine may decrease the antihypertensive activities of Pindolol.]
[B01AD01, streptokinase, The risk or severity of adverse effects can be increased when Streptokinase is combined with Pindolol.]
[J01GA01, streptomycin, Pindolol may decrease the excretion rate of Streptomycin which could result in a higher serum level.]
[L04AA27, fingolimod, Pindolol may increase the bradycardic activities of Fingolimod.]
[M03AB01, succinylcholine, The risk or severity of adverse effects can be increased when Succinylcholine is combined with Pindolol.]
[A02BX02, sucralfate, Sucralfate may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01CG01, sulbactam, Pindolol may decrease the excretion rate of Sulbactam which could result in a higher serum level.]
[J01EC02, sulfadiazine, The therapeutic efficacy of Sulfadiazine can be increased when used in combination with Pindolol.]
[J01EC01, sulfamethoxazole, The therapeutic efficacy of Sulfamethoxazole can be increased when used in combination with Pindolol.]
[S01AB02, sulfisoxazole, The therapeutic efficacy of Sulfisoxazole can be increased when used in combination with Pindolol.]
[M01AB02, sulindac, Sulindac may decrease the antihypertensive activities of Pindolol.]
[N05AL01, sulpiride, Sulpiride may increase the bradycardic activities of Pindolol.]
[N03AX03, sulthiame, The risk or severity of adverse effects can be increased when Pindolol is combined with Sulthiame.]
[A10BB04, glibornuride, The therapeutic efficacy of Glibornuride can be increased when used in combination with Pindolol.]
[A10BC01, glymidine, The therapeutic efficacy of Glymidine can be increased when used in combination with Pindolol.]
[M01AX04, apazone, Azapropazone may decrease the antihypertensive activities of Pindolol.]
[L01BB02, mercaptopurine, The risk or severity of adverse effects can be increased when Pindolol is combined with Mercaptopurine.]
[N06DA01, tacrine, Tacrine may increase the bradycardic activities of Pindolol.]
[L02BA01, tamoxifen, The metabolism of Tamoxifen can be decreased when combined with Pindolol.]
[N05CD07, temazepam, The risk or severity of adverse effects can be increased when Temazepam is combined with Pindolol.]
[R03CC03, terbutaline, Pindolol may decrease the bronchodilatory activities of Terbutaline.]
[B01AE07, dabigatran etexilate, Pindolol may decrease the excretion rate of Dabigatran etexilate which could result in a higher serum level.]
[G03BA03, testosterone, Testosterone may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N07XX06, tetrabenazine, The metabolism of Tetrabenazine can be decreased when combined with Pindolol.]
[S01HA03, tetracaine, The risk or severity of adverse effects can be increased when Pindolol is combined with Tetracaine.]
[S03AA02, tetracycline, Tetracycline may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DI02, ceftaroline fosamil, Ceftaroline fosamil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05AE05, lurasidone, The risk or severity of adverse effects can be increased when Pindolol is combined with Lurasidone.]
[A04AD10, dronabinol, Dronabinol may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[N04BC07, apomorphine, The risk or severity of adverse effects can be increased when Apomorphine is combined with Pindolol.]
[L04AX02, thalidomide, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Thalidomide.]
[R03DA07, theobromine, The risk or severity of adverse effects can be increased when Pindolol is combined with Theobromine.]
[R03DA04, theophylline, The metabolism of Theophylline can be decreased when combined with Pindolol.]
[P02CA02, thiabendazole, Thiabendazole may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[R06AD03, thiethylperazine, The serum concentration of Pindolol can be increased when it is combined with Thiethylperazine.]
[L01AC01, thiotepa, Thiotepa may increase the bradycardic activities of Pindolol.]
[N05CA19, thiopental, Thiopental may increase the hypotensive activities of Pindolol.]
[N05AB08, thioproperazine, The serum concentration of Pindolol can be increased when it is combined with Thioproperazine.]
[N05AC02, thioridazine, The metabolism of Pindolol can be decreased when combined with Thioridazine.]
[N05AF04, thiothixene, The risk or severity of adverse effects can be increased when Pindolol is combined with Thiothixene.]
[C01BB04, aprindine, The metabolism of Aprindine can be decreased when combined with Pindolol.]
[B02AB01, aprotinin, Aprotinin may increase the bradycardic activities of Pindolol.]
[G04BE06, moxisylyte, Moxisylyte may decrease the antihypertensive activities of Pindolol.]
[N05AL03, tiapride, The risk or severity of adverse effects can be increased when Pindolol is combined with Tiapride.]
[B01AC05, ticlopidine, The metabolism of Pindolol can be decreased when combined with Ticlopidine.]
[N02AX01, tilidine, The risk or severity of adverse effects can be increased when Pindolol is combined with Tilidine.]
[S01ED01, timolol, The risk or severity of adverse effects can be increased when Timolol is combined with Pindolol.]
[P01AB02, tinidazole, Tinidazole may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S01AA12, tobramycin, Pindolol may decrease the excretion rate of Tobramycin which could result in a higher serum level.]
[A10BB05, tolazamide, The therapeutic efficacy of Tolazamide can be increased when used in combination with Pindolol.]
[M02AX02, tolazoline, Pindolol may increase the orthostatic hypotensive activities of Tolazoline.]
[V04CA01, tolbutamide, The therapeutic efficacy of Tolbutamide can be increased when used in combination with Pindolol.]
[M02AA21, tolmetin, Tolmetin may decrease the antihypertensive activities of Pindolol.]
[M03BX04, tolperisone, The risk or severity of adverse effects can be increased when Pindolol is combined with Tolperisone.]
[N02AX02, tramadol, The risk or severity of serotonin syndrome can be increased when Pindolol is combined with Tramadol.]
[N06AF04, tranylcypromine, The metabolism of Pindolol can be decreased when combined with Tranylcypromine.]
[N06AX05, trazodone, The risk or severity of serotonin syndrome can be increased when Trazodone is combined with Pindolol.]
[L01XF01, tretinoin, The risk or severity of adverse effects can be increased when Tretinoin is combined with Pindolol.]
[C03DB02, triamterene, Triamterene may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CD05, triazolam, The risk or severity of adverse effects can be increased when Triazolam is combined with Pindolol.]
[C03AA06, trichlormethiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Trichlormethiazide.]
[A03AB12, mepenzolate, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Mepenzolate.]
[S01EB04, demecarium, Demecarium may increase the bradycardic activities of Pindolol.]
[A16AX12, trientine, Pindolol may decrease the excretion rate of Triethylenetetramine which could result in a higher serum level.]
[N05AB06, trifluoperazine, The serum concentration of Pindolol can be increased when it is combined with Trifluoperazine.]
[S01AD02, trifluridine, Trifluridine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05AD02, trifluperidol, The risk or severity of adverse effects can be increased when Pindolol is combined with Trifluperidol.]
[N05AA05, triflupromazine, The serum concentration of Pindolol can be increased when it is combined with Triflupromazine.]
[N04AA01, trihexyphenidyl, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Trihexyphenidyl.]
[A03AA05, trimebutine, The risk or severity of bradycardia can be increased when Trimebutine is combined with Pindolol.]
[S01ED04, metipranolol, Pindolol may increase the hypotensive activities of Metipranolol.]
[R06AD01, trimeprazine, The serum concentration of Pindolol can be increased when it is combined with Alimemazine.]
[N03AC02, trimethadione, The risk or severity of bradycardia can be increased when Trimethadione is combined with Pindolol.]
[C02BA01, trimethaphan, Pindolol may increase the hypotensive activities of Trimethaphan.]
[J01EA01, trimethoprim, The risk or severity of hyperkalemia can be increased when Trimethoprim is combined with Pindolol.]
[N06AA06, trimipramine, The metabolism of Trimipramine can be decreased when combined with Pindolol.]
[R06AC04, tripelennamine, The metabolism of Pindolol can be decreased when combined with Tripelennamine.]
[R06AX07, triprolidine, The risk or severity of adverse effects can be increased when Triprolidine is combined with Pindolol.]
[A03BB01, butylscopolamine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Butylscopolamine.]
[N06AX24, vilazodone, The metabolism of Pindolol can be decreased when combined with Vilazodone.]
[N06AX02, tryptophan, The risk or severity of adverse effects can be increased when Tryptophan is combined with Pindolol.]
[C09CA09, azilsartan medoxomil, Pindolol may increase the hypotensive activities of Azilsartan medoxomil.]
[M03AA02, tubocurarine, Tubocurarine may increase the bradycardic activities of Pindolol.]
[R03DX07, roflumilast, Pindolol may decrease the excretion rate of Roflumilast which could result in a higher serum level.]
[L01FX04, ipilimumab, Pindolol may decrease the excretion rate of Ipilimumab which could result in a higher serum level.]
[S01AA05, tyrothricin, Tyrothricin may increase the bradycardic activities of Pindolol.]
[R02AA14, oxyquinoline, Pindolol may decrease the excretion rate of Oxyquinoline which could result in a higher serum level.]
[L02BX03, abiraterone, The metabolism of Pindolol can be decreased when combined with Abiraterone.]
[A10BH05, linagliptin, The therapeutic efficacy of Linagliptin can be increased when used in combination with Pindolol.]
[J05AG05, rilpivirine, The metabolism of Pindolol can be decreased when combined with Rilpivirine.]
[S01AA28, vancomycin, Pindolol may decrease the excretion rate of Vancomycin which could result in a higher serum level.]
[N03AX21, ezogabine, The risk or severity of adverse effects can be increased when Pindolol is combined with Ezogabine.]
[B01AF01, rivaroxaban, Pindolol may decrease the excretion rate of Rivaroxaban which could result in a higher serum level.]
[R03AC18, indacaterol, Pindolol may decrease the bronchodilatory activities of Indacaterol.]
[C08DA01, verapamil, The risk or severity of adverse effects can be increased when Verapamil is combined with Pindolol.]
[N06AX09, viloxazine, The metabolism of Pindolol can be decreased when combined with Viloxazine.]
[L01CA01, vinblastine, The metabolism of Pindolol can be decreased when combined with Vinblastine.]
[C04AX07, vincamine, Pindolol may increase the hypotensive activities of Vincamine.]
[B03BA01, vitamin B12, Cyanocobalamin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[B01AA03, warfarin, Pindolol may decrease the excretion rate of Warfarin which could result in a higher serum level.]
[S01AA13, fusidic acid, The metabolism of Pindolol can be decreased when combined with Fusidic acid.]
[N01AX15, xenon, Xenon may decrease the antihypertensive activities of Pindolol.]
[C03BA10, xipamide, Xipamide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AF05, zuclopenthixol, Pindolol may increase the orthostatic hypotensive activities of Zuclopenthixol.]
[N03AX14, levetiracetam, The risk or severity of adverse effects can be increased when Pindolol is combined with Levetiracetam.]
[L01EC01, vemurafenib, The metabolism of Pindolol can be decreased when combined with Vemurafenib.]
[M05BA03, pamidronic acid, Pamidronic acid may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M05BA05, tiludronic acid, Pindolol may decrease the excretion rate of Tiludronic acid which could result in a higher serum level.]
[B06AC02, icatibant, Pindolol may decrease the excretion rate of Icatibant which could result in a higher serum level.]
[L01ED01, crizotinib, Crizotinib may increase the bradycardic activities of Pindolol.]
[A02BC04, rabeprazole, Pindolol may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N05AE04, ziprasidone, The risk or severity of adverse effects can be increased when Pindolol is combined with Ziprasidone.]
[G03AC10, drospirenone, Drospirenone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AC02, deferiprone, Pindolol may decrease the excretion rate of Deferiprone which could result in a higher serum level.]
[N02BA01, aspirin, Acetylsalicylic acid may decrease the antihypertensive activities of Pindolol.]
[L01EJ01, ruxolitinib, Ruxolitinib may increase the bradycardic activities of Pindolol.]
[G04BD07, tolterodine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Tolterodine.]
[J01DH04, doripenem, Pindolol may decrease the excretion rate of Doripenem which could result in a higher serum level.]
[C07AB03, atenolol, Atenolol may increase the hypotensive activities of Pindolol.]
[L01FA01, rituximab, Pindolol may increase the hypotensive activities of Rituximab.]
[M03AC04, atracurium, The risk or severity of adverse effects can be increased when Pindolol is combined with Atracurium.]
[S01FA01, atropine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Atropine.]
[M01CB03, auranofin, Pindolol may decrease the excretion rate of Auranofin which could result in a higher serum level.]
[B03XA04, peginesatide, Pindolol may decrease the excretion rate of Peginesatide which could result in a higher serum level.]
[L01BC07, azacitidine, Azacitidine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L04AX01, azathioprine, Pindolol may decrease the excretion rate of Azathioprine which could result in a higher serum level.]
[L01BC05, gemcitabine, Gemcitabine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DF01, aztreonam, Aztreonam may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[R02AB04, bacitracin, Bacitracin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[G04BE10, avanafil, Pindolol may increase the hypotensive activities of Avanafil.]
[M03BX01, baclofen, The risk or severity of adverse effects can be increased when Baclofen is combined with Pindolol.]
[A08AA11, lorcaserin, The metabolism of Pindolol can be decreased when combined with Lorcaserin.]
[G04BD12, mirabegron, The serum concentration of Pindolol can be increased when it is combined with Mirabegron.]
[V03AX03, cobicistat, The metabolism of Pindolol can be decreased when combined with Cobicistat.]
[L02BB04, enzalutamide, Pindolol may decrease the excretion rate of Enzalutamide which could result in a higher serum level.]
[C01CA18, octopamine, The therapeutic efficacy of Octopamine can be decreased when used in combination with Pindolol.]
[L01EX05, regorafenib, Regorafenib may increase the bradycardic activities of Pindolol.]
[N05CA04, barbital, Barbital may increase the hypotensive activities of Pindolol.]
[C01AA01, acetyldigitoxin, Pindolol may increase the bradycardic activities of Acetyldigitoxin.]
[D02BA02, octinoxate, Pindolol may decrease the excretion rate of Octinoxate which could result in a higher serum level.]
[S01GA07, brimonidine, Brimonidine may increase the antihypertensive activities of Pindolol.]
[N04BD02, rasagiline, Rasagiline may increase the hypotensive activities of Pindolol.]
[C08CA13, lercanidipine, The risk or severity of bradycardia can be increased when Lercanidipine is combined with Pindolol.]
[A03FA09, mosapride, The risk or severity of adverse effects can be increased when Pindolol is combined with Mosapride.]
[N06DA02, donepezil, Donepezil may increase the bradycardic activities of Pindolol.]
[N03AX22, perampanel, Perampanel may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[L04AA29, tofacitinib, Pindolol may increase the bradycardic activities of Tofacitinib.]
[N02CC03, zolmitriptan, The risk or severity of adverse effects can be increased when Zolmitriptan is combined with Pindolol.]
[R06AC06, thonzylamine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Thonzylamine.]
[G04BD10, darifenacin, The metabolism of Pindolol can be decreased when combined with Darifenacin.]
[V09IX04, fluorodeoxyglucose F18, Pindolol may decrease the excretion rate of Fludeoxyglucose (18F) which could result in a higher serum level.]
[N01AA01, ethyl ether, The risk or severity of adverse effects can be increased when Pindolol is combined with Diethyl ether.]
[H01CB05, pasireotide, Pindolol may increase the bradycardic activities of Pasireotide.]
[G04BE03, sildenafil, Sildenafil may increase the antihypertensive activities of Pindolol.]
[V08CA11, gadofosveset, Pindolol may decrease the excretion rate of Gadofosveset trisodium which could result in a higher serum level.]
[L01EA05, ponatinib, The metabolism of Ponatinib can be decreased when combined with Pindolol.]
[A16AX08, teduglutide, Pindolol may decrease the excretion rate of Teduglutide which could result in a higher serum level.]
[C04AX11, bencyclane, The risk or severity of bradycardia can be increased when Bencyclane is combined with Pindolol.]
[A10BH04, alogliptin, The therapeutic efficacy of Alogliptin can be increased when used in combination with Pindolol.]
[A16AX09, glycerol phenylbutyrate, The metabolism of Pindolol can be decreased when combined with Glycerol phenylbutyrate.]
[C03AA01, bendroflumethiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Bendroflumethiazide.]
[L04AX06, pomalidomide, The risk or severity of adverse effects can be increased when Pindolol is combined with Pomalidomide.]
[G03XC05, ospemifene, The metabolism of Pindolol can be decreased when combined with Ospemifene.]
[N02BA10, benorilate, Benorilate may decrease the antihypertensive activities of Pindolol.]
[N05AD07, benperidol, The risk or severity of adverse effects can be increased when Pindolol is combined with Benperidol.]
[A10BK02, canagliflozin, The therapeutic efficacy of Canagliflozin can be increased when used in combination with Pindolol.]
[A06AX06, tegaserod, The metabolism of Pindolol can be decreased when combined with Tegaserod.]
[H03AA04, tiratricol, The therapeutic efficacy of Tiratricol can be decreased when used in combination with Pindolol.]
[A10AE05, insulin detemir, The therapeutic efficacy of Insulin detemir can be increased when used in combination with Pindolol.]
[R02AD01, benzocaine, The risk or severity of adverse effects can be increased when Pindolol is combined with Benzocaine.]
[A10BX05, pramlintide, The therapeutic efficacy of Pramlintide can be increased when used in combination with Pindolol.]
[L03AA12, ancestim, Pindolol may decrease the excretion rate of Ancestim which could result in a higher serum level.]
[M01AH01, celecoxib, Celecoxib may decrease the antihypertensive activities of Pindolol.]
[N02CC02, naratriptan, The risk or severity of adverse effects can be increased when Naratriptan is combined with Pindolol.]
[L04AA18, everolimus, The metabolism of Pindolol can be decreased when combined with Everolimus.]
[N04AC01, benztropine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Benzatropine.]
[R02AX03, benzydamine, Benzydamine may decrease the antihypertensive activities of Pindolol.]
[L01EE01, trametinib, Pindolol may decrease the excretion rate of Trametinib which could result in a higher serum level.]
[P03AX06, benzyl alcohol, The risk or severity of adverse effects can be increased when Pindolol is combined with Benzyl alcohol.]
[V09AX05, florbetapir F-18, Pindolol may decrease the excretion rate of Florbetapir (18F) which could result in a higher serum level.]
[N06AX28, levomilnacipran, The risk or severity of adverse effects can be increased when Pindolol is combined with Levomilnacipran.]
[C08EA02, bepridil, The risk or severity of bradycardia can be increased when Bepridil is combined with Pindolol.]
[C02KX05, riociguat, Pindolol may increase the hypotensive activities of Riociguat.]
[A10BJ03, lixisenatide, The therapeutic efficacy of Lixisenatide can be increased when used in combination with Pindolol.]
[C02KX04, macitentan, Pindolol may increase the hypotensive activities of Macitentan.]
[L01EL01, ibrutinib, The metabolism of Ibrutinib can be decreased when combined with Pindolol.]
[N06AX26, vortioxetine, The risk or severity of adverse effects can be increased when Pindolol is combined with Vortioxetine.]
[G03AC08, etonogestrel, Etonogestrel may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N03AF04, eslicarbazepine, The risk or severity of adverse effects can be increased when Pindolol is combined with Eslicarbazepine.]
[J05AP08, sofosbuvir, Pindolol may decrease the excretion rate of Sofosbuvir which could result in a higher serum level.]
[N03AG04, vigabatrin, The risk or severity of adverse effects can be increased when Pindolol is combined with Vigabatrin.]
[A10BK01, dapagliflozin, The therapeutic efficacy of Dapagliflozin can be increased when used in combination with Pindolol.]
[C01CA27, droxidopa, Pindolol may decrease the bronchodilatory activities of Droxidopa.]
[C07AB04, acebutolol, The metabolism of Pindolol can be decreased when combined with Acebutolol.]
[N05CH03, tasimelteon, The risk or severity of adverse effects can be increased when Pindolol is combined with Tasimelteon.]
[L04AA32, apremilast, The metabolism of Pindolol can be increased when combined with Apremilast.]
[L02BG02, formestane, Pindolol may decrease the excretion rate of Formestane which could result in a higher serum level.]
[A16AA06, betaine, Betaine may increase the bradycardic activities of Pindolol.]
[S01ED02, betaxolol, Betaxolol may increase the hypotensive activities of Pindolol.]
[V03AB34, fomepizole, Pindolol may decrease the excretion rate of Fomepizole which could result in a higher serum level.]
[C02CC01, bethanidine, The therapeutic efficacy of Bethanidine can be decreased when used in combination with Pindolol.]
[A10BJ04, albiglutide, The therapeutic efficacy of Albiglutide can be increased when used in combination with Pindolol.]
[L04AC11, siltuximab, The metabolism of Pindolol can be increased when combined with Siltuximab.]
[L01ED02, ceritinib, Pindolol may increase the bradycardic activities of Ceritinib.]
[A03BA03, hyoscyamine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Hyoscyamine.]
[B01AA07, acenocoumarol, The risk or severity of adverse effects can be increased when Pindolol is combined with Acenocoumarol.]
[N01AX05, alfaxalone, The risk or severity of adverse effects can be increased when Pindolol is combined with Alfaxalone.]
[A10BK03, empagliflozin, The therapeutic efficacy of Empagliflozin can be increased when used in combination with Pindolol.]
[R03AC19, olodaterol, Pindolol may decrease the bronchodilatory activities of Olodaterol.]
[V08AA01, diatrizoic acid, Diatrizoate may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S01EE02, unoprostone, Pindolol may increase the hypotensive activities of Unoprostone.]
[D11AA01, glycopyrronium, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Glycopyrronium.]
[V08AA04, iothalamic acid, Diatrizoate may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05CM19, suvorexant, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Suvorexant.]
[A16AX10, eliglustat, The metabolism of Pindolol can be decreased when combined with Eliglustat.]
[J01XA05, oritavancin, The metabolism of Pindolol can be decreased when combined with Oritavancin.]
[S01AA15, dihydrostreptomycin, Dihydrostreptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05AA04, acepromazine, The serum concentration of Pindolol can be increased when it is combined with Acepromazine.]
[V04CX03, methacholine, Pindolol may increase the bronchoconstrictory activities of Methacholine.]
[A10BJ05, dulaglutide, The therapeutic efficacy of Dulaglutide can be increased when used in combination with Pindolol.]
[N04AA02, biperiden, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Biperiden.]
[L04AX05, pirfenidone, The metabolism of Pirfenidone can be decreased when combined with Pindolol.]
[S03AA06, gentamicin, Pindolol may decrease the excretion rate of Gentamicin which could result in a higher serum level.]
[J05AP09, dasabuvir, The metabolism of Dasabuvir can be decreased when combined with Pindolol.]
[B01AA01, dicumarol, The risk or severity of adverse effects can be increased when Pindolol is combined with Dicoumarol.]
[B01AF03, edoxaban, Pindolol may decrease the excretion rate of Edoxaban which could result in a higher serum level.]
[N06AX11, mirtazapine, Pindolol may increase the serotonergic activities of Mirtazapine.]
[L04AC10, secukinumab, The metabolism of Pindolol can be increased when combined with Secukinumab.]
[L01XH03, panobinostat, The metabolism of Pindolol can be decreased when combined with Panobinostat.]
[N02BE01, acetaminophen, Acetaminophen may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L01DC01, bleomycin, Bleomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[A03AA09, difemerine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Difemerine.]
[B01AA11, tioclomarol, The risk or severity of adverse effects can be increased when Pindolol is combined with Tioclomarol.]
[C01EB17, ivabradine, Pindolol may increase the bradycardic activities of Ivabradine.]
[J05AF08, adefovir dipivoxil, Adefovir dipivoxil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J05AP06, asunaprevir, The metabolism of Pindolol can be decreased when combined with Asunaprevir.]
[A07DA06, eluxadoline, The risk or severity of serotonin syndrome can be increased when Pindolol is combined with Eluxadoline.]
[N05AX16, brexpiprazole, Pindolol may increase the orthostatic hypotensive activities of Brexpiprazole.]
[A04AD14, rolapitant, The metabolism of Pindolol can be decreased when combined with Rolapitant.]
[G02CX02, flibanserin, The risk or severity of adverse effects can be increased when Pindolol is combined with Flibanserin.]
[N05AX15, cariprazine, The risk or severity of adverse effects can be increased when Pindolol is combined with Cariprazine.]
[A10BF01, acarbose, The therapeutic efficacy of Acarbose can be increased when used in combination with Pindolol.]
[M02AA25, aceclofenac, Aceclofenac may decrease the antihypertensive activities of Pindolol.]
[M01AB11, acemetacin, Acemetacin may decrease the antihypertensive activities of Pindolol.]
[S01EC01, acetazolamide, The risk or severity of adverse effects can be increased when Acetazolamide is combined with Pindolol.]
[A10AE06, insulin degludec, The therapeutic efficacy of Insulin degludec can be increased when used in combination with Pindolol.]
[N05AB07, acetophenazine, The serum concentration of Pindolol can be increased when it is combined with Acetophenazine.]
[A02BC03, lansoprazole, The metabolism of Pindolol can be decreased when combined with Lansoprazole.]
[V03AB37, idarucizumab, Pindolol may decrease the excretion rate of Idarucizumab which could result in a higher serum level.]
[L01CX01, trabectedin, The metabolism of Trabectedin can be decreased when combined with Pindolol.]
[J02AC05, isavuconazole, The metabolism of Pindolol can be decreased when combined with Isavuconazole.]
[J05AF13, tenofovir alafenamide, The serum concentration of Tenofovir alafenamide can be increased when it is combined with Pindolol.]
[L01XG03, ixazomib, Pindolol may decrease the excretion rate of Ixazomib which could result in a higher serum level.]
[B01AC27, selexipag, Pindolol may increase the hypotensive activities of Selexipag.]
[A10BB31, acetohexamide, The therapeutic efficacy of Acetohexamide can be increased when used in combination with Pindolol.]
[G04CA01, alfuzosin, Alfuzosin may increase the hypotensive activities of Pindolol.]
[M04AB05, lesinurad, Pindolol may decrease the excretion rate of Lesinurad which could result in a higher serum level.]
[N05CA05, aprobarbital, The risk or severity of adverse effects can be increased when Pindolol is combined with Aprobarbital.]
[M01AE16, alminoprofen, Alminoprofen may decrease the antihypertensive activities of Pindolol.]
[N03AX23, brivaracetam, The risk or severity of adverse effects can be increased when Pindolol is combined with Brivaracetam.]
[N05BA08, bromazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Bromazepam.]
[N04BC01, bromocriptine, The therapeutic efficacy of Bromocriptine can be increased when used in combination with Pindolol.]
[A02AD05, aluminum magnesium silicate, Pindolol may decrease the excretion rate of Almasilate which could result in a higher serum level.]
[A03AX08, alverine, The risk or severity of adverse effects can be increased when Pindolol is combined with Alverine.]
[R06AB01, brompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pindolol.]
[N06AA19, amineptin, The risk or severity of adverse effects can be increased when Pindolol is combined with Amineptine.]
[C08CA01, amlodipine, The risk or severity of bradycardia can be increased when Amlodipine is combined with Pindolol.]
[N06BX11, aniracetam, The risk or severity of adverse effects can be increased when Pindolol is combined with Aniracetam.]
[C03CA02, bumetanide, Bumetanide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N01BB01, bupivacaine, The serum concentration of Bupivacaine can be increased when it is combined with Pindolol.]
[C07AA19, bupranolol, Pindolol may increase the hypotensive activities of Bupranolol.]
[N07BC01, buprenorphine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Buprenorphine.]
[N05BE01, buspirone, The risk or severity of adverse effects can be increased when Buspirone is combined with Pindolol.]
[L01XX27, arsenic trioxide, The risk or severity of adverse effects can be increased when Pindolol is combined with Arsenic trioxide.]
[N06DA03, rivastigmine, Pindolol may increase the bradycardic activities of Rivastigmine.]
[M02AA03, clofezone, Pindolol may decrease the excretion rate of Rabeprazole which could result in a higher serum level.]
[N02AF01, butorphanol, The risk or severity of adverse effects can be increased when Butorphanol is combined with Pindolol.]
[S01GX07, azelastine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Azelastine.]
[L01XK03, rucaparib, The metabolism of Pindolol can be decreased when combined with Rucaparib.]
[A07EC04, balsalazide, Balsalazide may decrease the antihypertensive activities of Pindolol.]
[R03CC12, bambuterol, Pindolol may decrease the bronchodilatory activities of Bambuterol.]
[R03DA08, bamifylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Bamifylline.]
[A06AH05, naldemedine, Pindolol may decrease the excretion rate of Naldemedine which could result in a higher serum level.]
[N07XX16, deutetrabenazine, Pindolol may decrease the excretion rate of Deutetrabenazine which could result in a higher serum level.]
[N02BF02, pregabalin, The therapeutic efficacy of Pindolol can be increased when used in combination with Pregabalin.]
[N03AX30, beclamide, The risk or severity of adverse effects can be increased when Pindolol is combined with Beclamide.]
[N06BC01, caffeine, The risk or severity of adverse effects can be increased when Pindolol is combined with Caffeine.]
[C09AA07, benazepril, Benazepril may increase the hypotensive activities of Pindolol.]
[A10BX06, benfluorex, The therapeutic efficacy of Benfluorex can be increased when used in combination with Pindolol.]
[S01HA02, benoxinate, The risk or severity of adverse effects can be increased when Oxybuprocaine is combined with Pindolol.]
[A12AA04, calcium carbonate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium carbonate.]
[P01CA02, benznidazole, Pindolol may decrease the excretion rate of Benznidazole which could result in a higher serum level.]
[G04BA03, calcium chloride, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium chloride.]
[J01XX08, linezolid, The risk or severity of serotonin syndrome can be increased when Linezolid is combined with Pindolol.]
[J05AF06, abacavir, Pindolol may decrease the excretion rate of Abacavir which could result in a higher serum level.]
[J05AE09, tipranavir, The metabolism of Pindolol can be decreased when combined with Tipranavir.]
[D11AX03, calcium gluconate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium gluconate.]
[N07XX13, valbenazine, Pindolol may decrease the excretion rate of Valbenazine which could result in a higher serum level.]
[L04AB02, infliximab, The metabolism of Pindolol can be increased when combined with Infliximab.]
[A12AA01, calcium phosphate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium Phosphate.]
[N04BD03, safinamide, Safinamide may increase the hypotensive activities of Pindolol.]
[N07AB02, bethanechol, The risk or severity of adverse effects can be increased when Pindolol is combined with Bethanechol.]
[J01MA23, delafloxacin, Pindolol may decrease the excretion rate of Delafloxacin which could result in a higher serum level.]
[S01EB09, acetylcholine, The risk or severity of adverse effects can be increased when Pindolol is combined with Acetylcholine.]
[L01BC06, capecitabine, Pindolol may decrease the excretion rate of Capecitabine which could result in a higher serum level.]
[L01XX59, enasidenib, The metabolism of Enasidenib can be decreased when combined with Pindolol.]
[C07AB07, bisoprolol, The risk or severity of adverse effects can be increased when Bisoprolol is combined with Pindolol.]
[R03AC17, bitolterol, Pindolol may decrease the bronchodilatory activities of Bitolterol.]
[J05AG03, efavirenz, The risk or severity of adverse effects can be increased when Efavirenz is combined with Pindolol.]
[J01DC10, cefprozil, Cefprozil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C07AA17, bopindolol, Pindolol may increase the bradycardic activities of Bopindolol.]
[N04AA11, bornaprine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Bornaprine.]
[C01DX19, nesiritide, The risk or severity of adverse effects can be increased when Pindolol is combined with Nesiritide.]
[N05AD06, bromperidol, The risk or severity of adverse effects can be increased when Pindolol is combined with Bromperidol.]
[N05CD09, brotizolam, The risk or severity of adverse effects can be increased when Pindolol is combined with Brotizolam.]
[C03DA03, canrenone, Canrenone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R03BA02, budesonide, Pindolol may decrease the excretion rate of Budesonide which could result in a higher serum level.]
[C04AX20, buflomedil, Buflomedil may decrease the antihypertensive activities of Pindolol.]
[M01AB07, bumadizone, Bumadizone may decrease the antihypertensive activities of Pindolol.]
[N05CA03, butobarbital, The risk or severity of adverse effects can be increased when Pindolol is combined with Butobarbital.]
[J05AX18, letermovir, The metabolism of Letermovir can be decreased when combined with Pindolol.]
[N06AA15, butriptyline, The risk or severity of adverse effects can be increased when Pindolol is combined with Butriptyline.]
[C01AA02, acetyldigoxins, Pindolol may increase the bradycardic activities of Acetyldigoxin.]
[A10BJ06, semaglutide, The therapeutic efficacy of Semaglutide can be increased when used in combination with Pindolol.]
[N01BX04, capsaicin, Capsaicin may increase the bradycardic activities of Pindolol.]
[A10BK04, ertugliflozin, The therapeutic efficacy of Ertugliflozin can be increased when used in combination with Pindolol.]
[N05CA08, butylvinal, The risk or severity of adverse effects can be increased when Pindolol is combined with Vinylbital.]
[R06AX18, acrivastine, Pindolol may decrease the excretion rate of Acrivastine which could result in a higher serum level.]
[C09AA01, captopril, Pindolol may increase the hypotensive activities of Captopril.]
[S01EB02, carbachol, The risk or severity of adverse effects can be increased when Pindolol is combined with Carbamoylcholine.]
[L02BB05, apalutamide, Pindolol may decrease the excretion rate of Apalutamide which could result in a higher serum level.]
[N03AF01, carbamazepine, Pindolol may decrease the excretion rate of Carbamazepine which could result in a higher serum level.]
[A06AC08, calcium polycarbophil, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium polycarbophil.]
[A03AA03, camylofine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Camylofin.]
[R06AA08, carbinoxamine, The risk or severity of adverse effects can be increased when Carbinoxamine is combined with Pindolol.]
[C07AG02, carvedilol, The risk or severity of bradycardia can be increased when Carvedilol is combined with Pindolol.]
[B02BX09, fostamatinib, Fostamatinib may increase the antihypertensive activities of Pindolol.]
[N03AX24, cannabidiol, The risk or severity of adverse effects can be increased when Cannabidiol is combined with Pindolol.]
[L04AA37, baricitinib, Pindolol may decrease the excretion rate of Baricitinib which could result in a higher serum level.]
[J01DE01, cefepime, Cefepime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD10, cefetamet, Cefetamet may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD09, cefodizime, Cefodizime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DC11, ceforanide, Ceforanide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD13, cefpodoxime, Cefpodoxime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L01EC03, encorafenib, The metabolism of Encorafenib can be decreased when combined with Pindolol.]
[J01DD14, ceftibuten, Ceftibuten may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01GB14, plazomicin, Pindolol may decrease the excretion rate of Plazomicin which could result in a higher serum level.]
[C07AB08, celiprolol, Pindolol may decrease the bronchodilatory activities of Celiprolol.]
[H01CC03, elagolix, The metabolism of Elagolix can be decreased when combined with Pindolol.]
[P01BA07, tafenoquine, The metabolism of Tafenoquine can be decreased when combined with Pindolol.]
[A16AX14, migalastat, Pindolol may decrease the excretion rate of Migalastat which could result in a higher serum level.]
[N03AX17, stiripentol, The metabolism of Pindolol can be decreased when combined with Stiripentol.]
[L01EB07, dacomitinib, The metabolism of Dacomitinib can be decreased when combined with Pindolol.]
[S01GX12, cetirizine, The risk or severity of adverse effects can be increased when Cetirizine is combined with Pindolol.]
[N05CM04, carbromal, The risk or severity of adverse effects can be increased when Pindolol is combined with Carbromal.]
[A10BB06, carbutamide, The therapeutic efficacy of Carbutamide can be increased when used in combination with Pindolol.]
[N01BA04, chloroprocaine, The risk or severity of adverse effects can be increased when Pindolol is combined with Chloroprocaine.]
[D08AE05, chloroxylenol, Pindolol may decrease the excretion rate of Chloroxylenol which could result in a higher serum level.]
[R06AA06, chlorphenoxamine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Chlorphenoxamine.]
[M01AC05, lornoxicam, Lornoxicam may decrease the antihypertensive activities of Pindolol.]
[R03DA02, oxtriphylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxtriphylline.]
[N07XX15, inotersen, Inotersen may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M03BA02, carisoprodol, The risk or severity of adverse effects can be increased when Carisoprodol is combined with Pindolol.]
[R03BB08, revefenacin, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Revefenacin.]
[L04AA39, emapalumab, The metabolism of Pindolol can be increased when combined with Emapalumab.]
[L01AD01, carmustine, Carmustine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L01EX13, gilteritinib, The therapeutic efficacy of Pindolol can be decreased when used in combination with Gilteritinib.]
[A06AX05, prucalopride, Pindolol may decrease the excretion rate of Prucalopride which could result in a higher serum level.]
[C09AA08, cilazapril, Pindolol may increase the hypotensive activities of Cilazapril.]
[B01AC23, cilostazol, Pindolol may decrease the excretion rate of Cilostazol which could result in a higher serum level.]
[A03FA08, cinitapride, The risk or severity of adverse effects can be increased when Pindolol is combined with Cinitapride.]
[S01ED05, carteolol, Carteolol may increase the hypotensive activities of Pindolol.]
[P02BX04, triclabendazole, The metabolism of Pindolol can be decreased when combined with Triclabendazole.]
[N06AX27, esketamine, The risk or severity of adverse effects can be increased when Pindolol is combined with Esketamine.]
[L04AA42, siponimod, Siponimod may decrease the antihypertensive activities of Pindolol.]
[N06BA14, solriamfetol, The risk or severity of adverse effects can be increased when Pindolol is combined with Solriamfetol.]
[N06AX29, brexanolone, The risk or severity of adverse effects can be increased when Pindolol is combined with Brexanolone.]
[N05BA09, clobazam, The metabolism of Pindolol can be decreased when combined with Clobazam.]
[N05BA22, cloxazolam, The risk or severity of adverse effects can be increased when Pindolol is combined with Cloxazolam.]
[V03AE07, calcium acetate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium acetate.]
[C09CA06, candesartan, Pindolol may increase the hypotensive activities of Candesartan.]
[L04AB01, etanercept, The metabolism of Pindolol can be increased when combined with Etanercept.]
[J01DC04, cefaclor, Cefaclor may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB05, cefadroxil, Cefadroxil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DC03, cefamandole, Cefamandole may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB07, cefatrizine, Cefatrizine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB04, cefazolin, Cefazolin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DC09, cefmetazole, Cefmetazole may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DC06, cefonicid, Cefonicid may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD12, cefoperazone, Cefoperazone may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD01, cefotaxime, Cefotaxime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DC05, cefotetan, Cefotetan may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05AA06, cyamemazine, The serum concentration of Pindolol can be increased when it is combined with Cyamemazine.]
[J01DC07, cefotiam, Cefotiam may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DC01, cefoxitin, Cefoxitin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD03, cefsulodin, Cefsulodin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD02, ceftazidime, Ceftazidime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C03BX03, cicletanine, Cicletanine may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[J01DD07, ceftizoxime, Ceftizoxime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DD04, ceftriaxone, Ceftriaxone may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S01AA27, cefuroxime, Cefuroxime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M03BX08, cyclobenzaprine, The risk or severity of CNS depression can be increased when Cyclobenzaprine is combined with Pindolol.]
[L01EJ02, fedratinib, The metabolism of Pindolol can be decreased when combined with Fedratinib.]
[N07XX11, pitolisant, The metabolism of Pindolol can be decreased when combined with Pitolisant.]
[N04CX01, istradefylline, The metabolism of Istradefylline can be decreased when combined with Pindolol.]
[C03AA09, cyclothiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Cyclothiazide.]
[G04BE04, yohimbine, The risk or severity of adverse effects can be increased when Pindolol is combined with Yohimbine.]
[A10AE03, insulin, regular, pork, The therapeutic efficacy of Insulin pork can be increased when used in combination with Pindolol.]
[J01XX09, daptomycin, Daptomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB01, cephalexin, Cephalexin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB02, cephaloridine, Cefaloridine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB03, cephalothin, Cefalotin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB08, cephapirin, Cefapirin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J01DB09, cephradine, Cefradine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N02CC08, lasmiditan, The risk or severity of serotonin syndrome can be increased when Lasmiditan is combined with Pindolol.]
[A16AX16, givosiran, The serum concentration of Pindolol can be increased when it is combined with Givosiran.]
[M09AX08, golodirsen, Pindolol may decrease the excretion rate of Golodirsen which could result in a higher serum level.]
[R06AB06, dexbrompheniramine, The risk or severity of adverse effects can be increased when Dexbrompheniramine is combined with Pindolol.]
[R06AB02, dexchlorpheniramine, The metabolism of Pindolol can be decreased when combined with Dexchlorpheniramine.]
[S01XA12, dexpanthenol, Pindolol may decrease the excretion rate of Dexpanthenol which could result in a higher serum level.]
[N02AX03, dezocine, The risk or severity of adverse effects can be increased when Pindolol is combined with Dezocine.]
[N05CM21, lemborexant, The risk or severity of adverse effects can be increased when Pindolol is combined with Lemborexant.]
[N05AD10, lumateperone, The risk or severity of adverse effects can be increased when Pindolol is combined with Lumateperone.]
[M01AX21, diacetylrhein, The metabolism of Pindolol can be decreased when combined with Diacerein.]
[H02CA02, osilodrostat, The metabolism of Pindolol can be decreased when combined with Osilodrostat.]
[J05AE05, amprenavir, The metabolism of Amprenavir can be decreased when combined with Pindolol.]
[N02CC07, frovatriptan, The risk or severity of adverse effects can be increased when Pindolol is combined with Frovatriptan.]
[G04CB02, dutasteride, Dutasteride may decrease the antihypertensive activities of Pindolol.]
[N05CC04, dichloralphenazone, The risk or severity of adverse effects can be increased when Pindolol is combined with Dichloralphenazone.]
[R02AA03, dichlorobenzyl alcohol, Pindolol may decrease the excretion rate of Dichlorobenzyl alcohol which could result in a higher serum level.]
[G03DB08, dienogest, Pindolol may decrease the excretion rate of Dienogest which could result in a higher serum level.]
[A07DA04, difenoxin, The risk or severity of adverse effects can be increased when Pindolol is combined with Difenoxin.]
[N02AA08, dihydrocodeine, The risk or severity of adverse effects can be increased when Pindolol is combined with Dihydrocodeine.]
[N02CC06, eletriptan, The risk or severity of adverse effects can be increased when Eletriptan is combined with Pindolol.]
[M01AH02, rofecoxib, Rofecoxib may decrease the antihypertensive activities of Pindolol.]
[C08CA16, clevidipine, The risk or severity of bradycardia can be increased when Clevidipine is combined with Pindolol.]
[C01BD07, dronedarone, Dronedarone may increase the bradycardic activities of Pindolol.]
[N03AG02, dipropylacetamide, The risk or severity of adverse effects can be increased when Pindolol is combined with Valpromide.]
[N05BA02, chlordiazepoxide, The risk or severity of adverse effects can be increased when Chlordiazepoxide is combined with Pindolol.]
[C02AA06, methoserpidine, Pindolol may increase the hypotensive activities of Methoserpidine.]
[A03AA08, dihexyverine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Dihexyverine.]
[N04BX04, opicapone, The risk or severity of adverse effects can be increased when Pindolol is combined with Opicapone.]
[C01CA14, dopexamine, The therapeutic efficacy of Dopexamine can be decreased when used in combination with Pindolol.]
[G04BD09, trospium, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Trospium.]
[M01AC04, droxicam, Droxicam may decrease the antihypertensive activities of Pindolol.]
[V08CA05, mangafodipir, Pindolol may decrease the excretion rate of Mangafodipir which could result in a higher serum level.]
[L01EX22, selpercatinib, Selpercatinib may decrease the antihypertensive activities of Pindolol.]
[M02AA27, dexketoprofen, Dexketoprofen may decrease the antihypertensive activities of Pindolol.]
[N05CM02, chlormethiazole, The risk or severity of adverse effects can be increased when Pindolol is combined with Clomethiazole.]
[M03BB02, chlormezanone, The risk or severity of adverse effects can be increased when Pindolol is combined with Chlormezanone.]
[R02AD04, dyclonine, The risk or severity of adverse effects can be increased when Dyclonine is combined with Pindolol.]
[C08CA17, levamlodipine, The risk or severity of bradycardia can be increased when Levamlodipine is combined with Pindolol.]
[P01BB01, proguanil, The metabolism of Pindolol can be decreased when combined with Proguanil.]
[N05CD14, remimazolam, The risk or severity of sedation can be increased when Pindolol is combined with Remimazolam.]
[N02AX07, oliceridine, The risk or severity of hypotension, sedation, death, somnolence, and respiratory depression can be increased when Pindolol is combined with Oliceridine.]
[P01BA01, chloroquine, The metabolism of Pindolol can be decreased when combined with Chloroquine.]
[C03AA04, chlorothiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Chlorothiazide.]
[R06AB04, chlorpheniramine, The risk or severity of adverse effects can be increased when Pindolol is combined with Chlorpheniramine.]
[N05AA01, chlorpromazine, The metabolism of Pindolol can be decreased when combined with Chlorpromazine.]
[A10BB02, chlorpropamide, The therapeutic efficacy of Chlorpropamide can be increased when used in combination with Pindolol.]
[N05AF03, chlorprothixene, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Chlorprothixene.]
[C03BA04, chlorthalidone, Chlorthalidone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[M03BB03, chlorzoxazone, The risk or severity of adverse effects can be increased when Chlorzoxazone is combined with Pindolol.]
[A11CC05, cholecalciferol, The metabolism of Pindolol can be decreased when combined with Cholecalciferol.]
[N05BX03, etifoxine, The risk or severity of adverse effects can be increased when Pindolol is combined with Etifoxine.]
[N02BA07, ethenzamide, Ethenzamide may decrease the antihypertensive activities of Pindolol.]
[N02BA03, choline salicylate, Pindolol may decrease the excretion rate of Choline salicylate which could result in a higher serum level.]
[N06BX18, vinpocetine, The risk or severity of bradycardia can be increased when Vinpocetine is combined with Pindolol.]
[N05BA18, ethyl loflazepate, The risk or severity of adverse effects can be increased when Pindolol is combined with Ethyl loflazepate.]
[M01AB08, etodolac, Etodolac may decrease the antihypertensive activities of Pindolol.]
[M02AA06, etofenamate, Etofenamate may decrease the antihypertensive activities of Pindolol.]
[B06AC06, berotralstat, The metabolism of Pindolol can be decreased when combined with Berotralstat.]
[M01AX25, chondroitin sulfates, Pindolol may decrease the excretion rate of Chondroitin sulfate which could result in a higher serum level.]
[L01FX21, naxitamab, Naxitamab may decrease the antihypertensive activities of Pindolol.]
[C01DX22, vericiguat, The risk or severity of adverse effects can be increased when Pindolol is combined with Vericiguat.]
[M03BA05, febarbamate, The risk or severity of adverse effects can be increased when Pindolol is combined with Febarbamate.]
[N03AX10, felbamate, The risk or severity of adverse effects can be increased when Felbamate is combined with Pindolol.]
[M01AE05, fenbufen, Fenbufen may decrease the antihypertensive activities of Pindolol.]
[N06BA10, fenethylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Fenethylline.]
[C01CA19, fenoldopam, Fenoldopam may increase the hypotensive activities of Pindolol.]
[N06BA08, fenozolone, Fenozolone may decrease the antihypertensive activities of Pindolol.]
[G04CB01, finasteride, Finasteride may decrease the antihypertensive activities of Pindolol.]
[J01DD15, cefdinir, Cefdinir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S02BA08, fluocinolone acetonide, Fluocinolone acetonide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N02BG07, flupirtine, Pindolol may decrease the excretion rate of Flupirtine which could result in a higher serum level.]
[R03CC15, formoterol, Pindolol may decrease the bronchodilatory activities of Formoterol.]
[A10AF01, insulin, regular, human, The therapeutic efficacy of Insulin human can be increased when used in combination with Pindolol.]
[L04AA50, ponesimod, The risk or severity of bradycardia can be increased when Ponesimod is combined with Pindolol.]
[N01AB05, trichloroethylene, The risk or severity of adverse effects can be increased when Pindolol is combined with Trichloroethylene.]
[L03AB10, peginterferon alfa-2b, The metabolism of Pindolol can be decreased when combined with Peginterferon alfa-2b.]
[H04AA02, dasiglucagon, The therapeutic efficacy of Pindolol can be decreased when used in combination with Dasiglucagon.]
[A02BA01, cimetidine, The metabolism of Pindolol can be decreased when combined with Cimetidine.]
[N02BF01, gabapentin, The risk or severity of adverse effects can be increased when Pindolol is combined with Gabapentin.]
[V08CA04, gadoteridol, Gadoteridol may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N07CA02, cinnarizine, The risk or severity of bradycardia can be increased when Cinnarizine is combined with Pindolol.]
[S03AA07, ciprofloxacin, Ciprofloxacin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L01XA01, cisplatin, Pindolol may decrease the excretion rate of Cisplatin which could result in a higher serum level.]
[N06AB04, citalopram, The risk or severity of adverse effects can be increased when Pindolol is combined with Citalopram.]
[C03DA05, finerenone, Finerenone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P01CA03, fexinidazole, The risk or severity of adverse effects can be increased when Pindolol is combined with Fexinidazole.]
[V09AB03, ioflupane I-123, Pindolol may decrease the excretion rate of Ioflupane I-123 which could result in a higher serum level.]
[V09AA01, technetium Tc 99m exametazime, Pindolol may decrease the excretion rate of Technetium Tc-99m exametazime which could result in a higher serum level.]
[V09AX06, florbetaben f-18, Pindolol may decrease the excretion rate of Florbetaben (18F) which could result in a higher serum level.]
[R06AA04, clemastine, The risk or severity of adverse effects can be increased when Clemastine is combined with Pindolol.]
[M01AG01, mefenamic acid, Mefenamic acid may decrease the antihypertensive activities of Pindolol.]
[A10BB12, glimepiride, The therapeutic efficacy of Glimepiride can be increased when used in combination with Pindolol.]
[A10BB08, gliquidone, The therapeutic efficacy of Gliquidone can be increased when used in combination with Pindolol.]
[R03CC13, clenbuterol, Pindolol may decrease the bronchodilatory activities of Clenbuterol.]
[A12AA02, calcium glubionate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium glubionate anhydrous.]
[N06AX25, St. John's wort extract, The risk or severity of adverse effects can be increased when Pindolol is combined with St. John's Wort.]
[L03AB15, ropeginterferon alfa-2b, The risk or severity of neuropsychiatric effects can be increased when Ropeginterferon alfa-2b is combined with Pindolol.]
[N01BB10, levobupivacaine, The risk or severity of adverse effects can be increased when Pindolol is combined with Levobupivacaine.]
[N06AA04, clomipramine, The metabolism of Clomipramine can be decreased when combined with Pindolol.]
[N03AE01, clonazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Clonazepam.]
[S01EA04, clonidine, The risk or severity of sedation can be increased when Clonidine is combined with Pindolol.]
[J05AH02, oseltamivir, Oseltamivir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[A10BX16, tirzepatide, The therapeutic efficacy of Tirzepatide can be increased when used in combination with Pindolol.]
[C03BA03, clopamide, Clopamide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AH06, clothiapine, The risk or severity of adverse effects can be increased when Pindolol is combined with Clothiapine.]
[N05BA21, clotiazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Clotiazepam.]
[A04AA01, ondansetron, The risk or severity of adverse effects can be increased when Ondansetron is combined with Pindolol.]
[A04AA02, granisetron, The risk or severity of adverse effects can be increased when Granisetron is combined with Pindolol.]
[N05AH02, clozapine, The metabolism of Pindolol can be decreased when combined with Clozapine.]
[A10BX01, guar gum, The therapeutic efficacy of Guar gum can be increased when used in combination with Pindolol.]
[A10BK06, sotagliflozin, The therapeutic efficacy of Sotagliflozin can be increased when used in combination with Pindolol.]
[J01GB12, arbekacin, Pindolol may decrease the excretion rate of Arbekacin which could result in a higher serum level.]
[N05BA13, halazepam, The risk or severity of adverse effects can be increased when Halazepam is combined with Pindolol.]
[S02DA02, cocaine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Cocaine.]
[C02KB01, metyrosine, Pindolol may increase the sedative activities of Metyrosine.]
[L04AC21, bimekizumab, The metabolism of Pindolol can be increased when combined with Bimekizumab.]
[M01AX13, proquazone, Proquazone may decrease the antihypertensive activities of Pindolol.]
[R05DA04, codeine, The risk or severity of adverse effects can be increased when Codeine is combined with Pindolol.]
[M03AC05, hexafluorenium, Hexafluronium may increase the bradycardic activities of Pindolol.]
[M04AC01, colchicine, Pindolol may decrease the excretion rate of Colchicine which could result in a higher serum level.]
[A03AB10, hexocyclium, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Hexocyclium.]
[A03BB06, homatropine methylbromide, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Homatropine methylbromide.]
[J01XB01, colistin, Pindolol may decrease the excretion rate of Colistin which could result in a higher serum level.]
[J01DE02, cefpirome, Cefpirome may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N01AB07, desflurane, The risk or severity of adverse effects can be increased when Pindolol is combined with Desflurane.]
[A04AA03, tropisetron, The risk or severity of adverse effects can be increased when Pindolol is combined with Tropisetron.]
[C04AX28, ifenprodil, The risk or severity of adverse effects can be increased when Pindolol is combined with Ifenprodil.]
[A10BX03, nateglinide, The therapeutic efficacy of Nateglinide can be increased when used in combination with Pindolol.]
[N02BA16, imidazole-2-hydroxybenzoate, Imidazole salicylate may decrease the antihypertensive activities of Pindolol.]
[H01AC03, mecasermin, The therapeutic efficacy of Mecasermin can be increased when used in combination with Pindolol.]
[A10AE04, insulin glargine, The therapeutic efficacy of Insulin glargine can be increased when used in combination with Pindolol.]
[R03BA08, ciclesonide, The metabolism of Ciclesonide can be decreased when combined with Pindolol.]
[B01AC10, indobufen, Indobufen may decrease the antihypertensive activities of Pindolol.]
[R06AX27, desloratadine, The risk or severity of adverse effects can be increased when Pindolol is combined with Desloratadine.]
[J05AB14, valganciclovir, Pindolol may decrease the excretion rate of Valganciclovir which could result in a higher serum level.]
[C05BB03, invert sugar, Pindolol may decrease the excretion rate of Invert sugar which could result in a higher serum level.]
[V08AB09, iodixanol, Pindolol may decrease the excretion rate of Iodixanol which could result in a higher serum level.]
[V08AB05, iopromide, Pindolol may decrease the excretion rate of Iopromide which could result in a higher serum level.]
[V08AB07, ioversol, Pindolol may decrease the excretion rate of Ioversol which could result in a higher serum level.]
[V08AB12, ioxilan, Pindolol may decrease the excretion rate of Ioxilan which could result in a higher serum level.]
[M01AH03, valdecoxib, Valdecoxib may decrease the antihypertensive activities of Pindolol.]
[H01AX01, pegvisomant, Pegvisomant may increase the bradycardic activities of Pindolol.]
[C01AA06, lanatoside C, Pindolol may increase the bradycardic activities of Lanatoside C.]
[A03AX10, isometheptene, The therapeutic efficacy of Isometheptene can be decreased when used in combination with Pindolol.]
[N02CC05, almotriptan, The risk or severity of adverse effects can be increased when Almotriptan is combined with Pindolol.]
[M01AH04, parecoxib, Parecoxib may decrease the antihypertensive activities of Pindolol.]
[J02AC02, itraconazole, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Itraconazole.]
[B01AB12, bemiparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Bemiparin.]
[S01AD03, acyclovir, Acyclovir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05BA10, ketazolam, The risk or severity of adverse effects can be increased when Pindolol is combined with Ketazolam.]
[M01AA06, kebuzone, Kebuzone may decrease the antihypertensive activities of Pindolol.]
[L01EA01, imatinib, The serum concentration of Pindolol can be increased when it is combined with Imatinib.]
[S01EE04, travoprost, Travoprost may increase the hypotensive activities of Pindolol.]
[S01EE03, bimatoprost, Bimatoprost may increase the hypotensive activities of Pindolol.]
[C08CA09, lacidipine, Pindolol may increase the hypotensive activities of Lacidipine.]
[N03AX09, lamotrigine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Lamotrigine.]
[N07BC04, lofexidine, The therapeutic efficacy of Pindolol can be increased when used in combination with Lofexidine.]
[M01AB09, lonazolac, Lonazolac may decrease the antihypertensive activities of Pindolol.]
[N05CD06, lormetazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Lormetazepam.]
[M02AA31, loxoprofen, Loxoprofen may decrease the antihypertensive activities of Pindolol.]
[J01DC08, loracarbef, Loracarbef may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C09AA03, lisinopril, Lisinopril may increase the hypotensive activities of Pindolol.]
[A06AD01, magnesium carbonate, Pindolol may decrease the excretion rate of Magnesium carbonate which could result in a higher serum level.]
[C08CA11, manidipine, The risk or severity of bradycardia can be increased when Manidipine is combined with Pindolol.]
[A03AA04, mebeverine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Mebeverine.]
[N06AX13, medifoxamine, The risk or severity of adverse effects can be increased when Pindolol is combined with Medifoxamine.]
[A08AA09, mefenorex, Mefenorex may decrease the antihypertensive activities of Pindolol.]
[C07AA14, mepindolol, Pindolol may increase the bradycardic activities of Mepindolol.]
[R06AD07, mequitazine, The metabolism of Mequitazine can be decreased when combined with Pindolol.]
[J01DH02, meropenem, Meropenem may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N04AA03, methixene, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Metixene.]
[C04AX01, cyclandelate, The risk or severity of bradycardia can be increased when Cyclandelate is combined with Pindolol.]
[R03CB02, methoxyphenamine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Methoxyphenamine.]
[R06AE03, cyclizine, The risk or severity of adverse effects can be increased when Pindolol is combined with Cyclizine.]
[N05CA10, cyclobarbital, The risk or severity of adverse effects can be increased when Pindolol is combined with Cyclobarbital.]
[C03DA04, eplerenone, Eplerenone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AD03, metylperon, The risk or severity of adverse effects can be increased when Pindolol is combined with Melperone.]
[C03AA07, cyclopenthiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Cyclopenthiazide.]
[A10BF02, miglitol, The therapeutic efficacy of Miglitol can be increased when used in combination with Pindolol.]
[J05AF07, tenofovir disoproxil, Tenofovir disoproxil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N06AX07, minaprine, Minaprine may increase the bradycardic activities of Pindolol.]
[S01XA18, cyclosporine, The metabolism of Pindolol can be decreased when combined with Cyclosporine.]
[N06AG02, moclobemide, Moclobemide may increase the hypotensive activities of Pindolol.]
[R06AX02, cyproheptadine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Cyproheptadine.]
[C09AA13, moexipril, Moexipril may increase the hypotensive activities of Pindolol.]
[M02AA02, mofebutazone, Mofebutazone may decrease the antihypertensive activities of Pindolol.]
[M01AX22, morniflumate, Morniflumate may decrease the antihypertensive activities of Pindolol.]
[C03XA02, conivaptan, Conivaptan may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C02AC05, moxonidine, The therapeutic efficacy of Moxonidine can be decreased when used in combination with Pindolol.]
[G04BE09, vardenafil, Vardenafil may increase the antihypertensive activities of Pindolol.]
[M01AH05, etoricoxib, Etoricoxib may decrease the antihypertensive activities of Pindolol.]
[L01AX04, dacarbazine, Dacarbazine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M03CA01, dantrolene, The risk or severity of adverse effects can be increased when Pindolol is combined with Dantrolene.]
[N06BX04, deanol, The risk or severity of adverse effects can be increased when Pindolol is combined with Deanol.]
[C02CC04, debrisoquin, Pindolol may increase the hypotensive activities of Debrisoquine.]
[A04AD11, nabilone, Nabilone may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[M01AX01, nabumetone, Nabumetone may decrease the antihypertensive activities of Pindolol.]
[N07BB05, nalmefene, Pindolol may decrease the excretion rate of Nalmefene which could result in a higher serum level.]
[B05XA15, potassium lactate, Potassium lactate may increase the hyperkalemic activities of Pindolol.]
[N05BA16, nordazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Nordazepam.]
[C07AB12, nebivolol, The therapeutic efficacy of Nebivolol can be decreased when used in combination with Pindolol.]
[S01GX04, nedocromil, Nedocromil may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N06AX06, nefazodone, The risk or severity of adverse effects can be increased when Pindolol is combined with Nefazodone.]
[N05CM16, niaprazine, The risk or severity of adverse effects can be increased when Pindolol is combined with Niaprazine.]
[C01DX16, nicorandil, Nicorandil may increase the hypotensive activities of Pindolol.]
[L02BB02, nilutamide, Nilutamide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N03AG06, tiagabine, The risk or severity of adverse effects can be increased when Tiagabine is combined with Pindolol.]
[C01CA23, theodrenaline, The risk or severity of adverse effects can be increased when Pindolol is combined with Theodrenaline.]
[M03AC11, cisatracurium, The risk or severity of adverse effects can be increased when Cisatracurium is combined with Pindolol.]
[C01CA05, norfenefrine, The therapeutic efficacy of Norfenefrine can be decreased when used in combination with Pindolol.]
[R05DA06, normethadone, The risk or severity of adverse effects can be increased when Pindolol is combined with Normethadone.]
[B01AX05, fondaparinux, Fondaparinux may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N06AB10, escitalopram, The risk or severity of serotonin syndrome can be increased when Pindolol is combined with Escitalopram.]
[G04BD08, solifenacin, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Solifenacin.]
[A07EC03, olsalazine, Olsalazine may decrease the antihypertensive activities of Pindolol.]
[N06AA01, desipramine, The metabolism of Pindolol can be decreased when combined with Desipramine.]
[C01AA07, deslanoside, Pindolol may increase the bradycardic activities of Deslanoside.]
[H01BA02, desmopressin, Desmopressin may decrease the antihypertensive activities of Pindolol.]
[V04CH02, indigo carmine, Pindolol may decrease the excretion rate of Indigotindisulfonic acid which could result in a higher serum level.]
[J01DH03, ertapenem, Ertapenem may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C09XA02, aliskiren, Pindolol may increase the hypotensive activities of Aliskiren.]
[M01AE12, oxaprozin, Oxaprozin may decrease the antihypertensive activities of Pindolol.]
[N03AF02, oxcarbazepine, The risk or severity of adverse effects can be increased when Oxcarbazepine is combined with Pindolol.]
[N06BX07, oxiracetam, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxiracetam.]
[N04AA08, dexetimide, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Dexetimide.]
[G04BD04, oxybutynin, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Oxybutynin.]
[A08AA04, dexfenfluramine, The risk or severity of serotonin syndrome can be increased when Pindolol is combined with Dexfenfluramine.]
[A03AA01, oxyphencyclimine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Oxyphencyclimine.]
[L04AB04, adalimumab, The metabolism of Pindolol can be increased when combined with Adalimumab.]
[L01EB01, gefitinib, The metabolism of Pindolol can be decreased when combined with Gefitinib.]
[N06BA02, dextroamphetamine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Amphetamine.]
[R05DA09, dextromethorphan, The risk or severity of adverse effects can be increased when Dextromethorphan is combined with Pindolol.]
[N03AC01, paramethadione, The risk or severity of adverse effects can be increased when Paramethadione is combined with Pindolol.]
[N02AC01, dextromoramide, The risk or severity of adverse effects can be increased when Pindolol is combined with Dextromoramide.]
[N06AB05, paroxetine, The metabolism of Pindolol can be decreased when combined with Paroxetine.]
[N07BC06, heroin, The risk or severity of adverse effects can be increased when Pindolol is combined with Diamorphine.]
[C01DA05, pentaerythritol tetranitrate, Pindolol may decrease the excretion rate of Pentaerythritol tetranitrate which could result in a higher serum level.]
[C04AD01, pentifylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Pentifylline.]
[P03AC04, permethrin, Pindolol may decrease the excretion rate of Permethrin which could result in a higher serum level.]
[N05BA01, diazepam, The risk or severity of adverse effects can be increased when Diazepam is combined with Pindolol.]
[N03AX07, phenacemide, The risk or severity of adverse effects can be increased when Pindolol is combined with Phenacemide.]
[V03AH01, diazoxide, Diazoxide may increase the hypotensive activities of Pindolol.]
[N03AD02, phensuximide, The risk or severity of adverse effects can be increased when Phensuximide is combined with Pindolol.]
[N06AA08, dibenzepin, The risk or severity of adverse effects can be increased when Pindolol is combined with Dibenzepin.]
[S02DA04, dibucaine, Cinchocaine may increase the bradycardic activities of Pindolol.]
[R05DA08, pholcodine, Pindolol may decrease the excretion rate of Pholcodine which could result in a higher serum level.]
[S01EC02, dichlorphenamide, Diclofenamide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[S01BC03, diclofenac, Diclofenac may decrease the antihypertensive activities of Pindolol.]
[J05AD01, foscarnet, Foscarnet may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[A03AA07, dicyclomine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Dicyclomine.]
[J05AF02, didanosine, Didanosine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C02DG01, pinacidil, Pindolol may increase the hypotensive activities of Pinacidil.]
[A03AX04, pinaverium, The risk or severity of bradycardia can be increased when Pinaverium is combined with Pindolol.]
[A10BG03, pioglitazone, The therapeutic efficacy of Pioglitazone can be increased when used in combination with Pindolol.]
[N05AD05, pipamperone, The risk or severity of adverse effects can be increased when Pindolol is combined with Pipamperone.]
[A03AB14, pipenzolate, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Pipenzolate.]
[L01EB02, erlotinib, The metabolism of Erlotinib can be decreased when combined with Pindolol.]
[R03CC07, pirbuterol, Pindolol may decrease the bronchodilatory activities of Pirbuterol.]
[C03CA03, piretanide, Piretanide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[P02CB02, diethylcarbamazine, Diethylcarbamazine may increase the bradycardic activities of Pindolol.]
[A08AA03, diethylpropion, The therapeutic efficacy of Pindolol can be decreased when used in combination with Diethylpropion.]
[C08CA03, isradipine, The risk or severity of bradycardia can be increased when Isradipine is combined with Pindolol.]
[D07XC04, diflucortolone, Pindolol may decrease the excretion rate of Difluocortolone which could result in a higher serum level.]
[A03AB11, poldine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Poldine.]
[N02BA11, diflunisal, Diflunisal may decrease the antihypertensive activities of Pindolol.]
[C01AA04, digitoxin, Pindolol may increase the bradycardic activities of Digitoxin.]
[C01AA05, digoxin, Pindolol may decrease the excretion rate of Digoxin which could result in a higher serum level.]
[C02DB01, dihydralazine, Pindolol may increase the hypotensive activities of Dihydralazine.]
[C04AE04, dihydroergocristine, Pindolol may increase the vasoconstricting activities of Dihydroergocristine.]
[N02CA01, dihydroergotamine, Pindolol may increase the vasoconstricting activities of Dihydroergotamine.]
[N02AA03, hydromorphone, The risk or severity of adverse effects can be increased when Hydromorphone is combined with Pindolol.]
[L04AX04, lenalidomide, Lenalidomide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J05AE08, atazanavir, Atazanavir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[B01AC21, treprostinil, Treprostinil may increase the hypotensive activities of Pindolol.]
[H03BC01, potassium perchlorate, Potassium perchlorate may increase the hyperkalemic activities of Pindolol.]
[V03AB04, pralidoxime, Pralidoxime may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[D04AB07, pramoxine, The risk or severity of adverse effects can be increased when Pindolol is combined with Pramocaine.]
[C08DB01, diltiazem, The risk or severity of bradycardia can be increased when Diltiazem is combined with Pindolol.]
[R06AA11, dimenhydrinate, The risk or severity of adverse effects can be increased when Pindolol is combined with Dimenhydrinate.]
[V03AB09, dimercaprol, Pindolol may decrease the excretion rate of Dimercaprol which could result in a higher serum level.]
[M03BX03, pridinol, The risk or severity of adverse effects can be increased when Pindolol is combined with Pridinol.]
[R06AB03, dimethindene, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Dimetindene.]
[R03CC08, procaterol, Pindolol may decrease the bronchodilatory activities of Procaterol.]
[M02AX03, dimethyl sulfoxide, The metabolism of Pindolol can be decreased when combined with Dimethyl sulfoxide.]
[N03AG05, progabide, The risk or severity of adverse effects can be increased when Progabide is combined with Pindolol.]
[N06BC02, propentofylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Propentofylline.]
[N02BB04, propyphenazone, Propyphenazone may decrease the antihypertensive activities of Pindolol.]
[M01AB14, proglumetacin, Proglumetacin may decrease the antihypertensive activities of Pindolol.]
[R03DA03, proxyphylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Proxyphylline.]
[R06AA02, diphenhydramine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Diphenhydramine.]
[A07DA01, diphenoxylate, The risk or severity of adverse effects can be increased when Pindolol is combined with Diphenoxylate.]
[N05CD10, quazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Quazepam.]
[C09AA06, quinapril, Quinapril may increase the hypotensive activities of Pindolol.]
[B01AC07, dipyridamole, Dipyridamole may increase the bradycardic activities of Pindolol.]
[N06BA11, dexmethylphenidate, Dexmethylphenidate may decrease the antihypertensive activities of Pindolol.]
[N06AA23, quinupramine, The risk or severity of adverse effects can be increased when Pindolol is combined with Quinupramine.]
[A03FA02, cisapride, The metabolism of Pindolol can be decreased when combined with Cisapride.]
[C09AA05, ramipril, Ramipril may increase the hypotensive activities of Pindolol.]
[N05AL04, remoxipride, The risk or severity of adverse effects can be increased when Remoxipride is combined with Pindolol.]
[R03CC14, reproterol, The therapeutic efficacy of Reproterol can be decreased when used in combination with Pindolol.]
[S01AX06, resorcinol, Pindolol may decrease the excretion rate of Resorcinol which could result in a higher serum level.]
[C01BA03, disopyramide, Disopyramide may increase the bradycardic activities of Pindolol.]
[N07AA03, distigmine, Distigmine may increase the bradycardic activities of Pindolol.]
[S02AA12, rifamycin SV, The metabolism of Pindolol can be increased when combined with Rifamycin.]
[J04AB05, rifapentine, The metabolism of Pindolol can be increased when combined with Rifapentine.]
[D06AX11, rifaximin, The metabolism of Pindolol can be increased when combined with Rifaximin.]
[N07XX02, riluzole, The risk or severity of adverse effects can be increased when Riluzole is combined with Pindolol.]
[N05AX08, risperidone, Pindolol may increase the hypotensive activities of Risperidone.]
[R06AE09, levocetirizine, The risk or severity of adverse effects can be increased when Pindolol is combined with Levocetirizine.]
[N01BB09, ropivacaine, The risk or severity of adverse effects can be increased when Ropivacaine is combined with Pindolol.]
[L01EX01, sunitinib, The therapeutic efficacy of Sunitinib can be increased when used in combination with Pindolol.]
[C03XA01, tolvaptan, Tolvaptan may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[L01XG01, bortezomib, The metabolism of Bortezomib can be decreased when combined with Pindolol.]
[G04BE08, tadalafil, Tadalafil may increase the hypotensive activities of Pindolol.]
[S01BC05, ketorolac, Ketorolac may decrease the antihypertensive activities of Pindolol.]
[C02KX02, ambrisentan, Pindolol may increase the hypotensive activities of Ambrisentan.]
[C01EB18, ranolazine, The serum concentration of Pindolol can be increased when it is combined with Ranolazine.]
[N02BA06, salsalate, Salsalate may decrease the antihypertensive activities of Pindolol.]
[R03AC12, salmeterol, Pindolol may decrease the bronchodilatory activities of Salmeterol.]
[H05BA01, salmon calcitonin, Salmon calcitonin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C01CA07, dobutamine, Pindolol may decrease the bronchodilatory activities of Dobutamine.]
[A03FA03, domperidone, The metabolism of Domperidone can be decreased when combined with Pindolol.]
[C01CA04, dopamine, Dopamine may decrease the antihypertensive activities of Pindolol.]
[N06AA16, dothiepin, The metabolism of Pindolol can be decreased when combined with Dosulepin.]
[R07AB01, doxapram, Doxapram may decrease the antihypertensive activities of Pindolol.]
[N06AA12, doxepin, Pindolol may increase the orthostatic hypotensive activities of Doxepin.]
[L01DB01, doxorubicin, The metabolism of Pindolol can be decreased when combined with Doxorubicin.]
[J01AA02, doxycycline, Doxycycline may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[R06AA09, doxylamine, Doxylamine may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[N06AB06, sertraline, The risk or severity of adverse effects can be increased when Pindolol is combined with Sertraline.]
[N01AB08, sevoflurane, The risk or severity of adverse effects can be increased when Pindolol is combined with Sevoflurane.]
[N05AD08, droperidol, Droperidol may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[A08AA10, sibutramine, The risk or severity of adverse effects can be increased when Pindolol is combined with Sibutramine.]
[C10AA01, simvastatin, The metabolism of Simvastatin can be decreased when combined with Pindolol.]
[V03AG05, sodium phosphate, Sodium phosphate, monobasic may increase the hyperkalemic activities of Pindolol.]
[A12CA02, sodium sulfate, Pindolol may decrease the excretion rate of Sodium sulfate which could result in a higher serum level.]
[C09AA11, spirapril, Pindolol may increase the hypotensive activities of Spirapril.]
[R03DA01, dyphylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Dyphylline.]
[N05AL02, sultopride, The risk or severity of adverse effects can be increased when Pindolol is combined with Sultopride.]
[N02CC01, sumatriptan, The risk or severity of adverse effects can be increased when Sumatriptan is combined with Pindolol.]
[V04CX07, edrophonium, Edrophonium may increase the bradycardic activities of Pindolol.]
[C07AB13, talinolol, Pindolol may increase the hypotensive activities of Talinolol.]
[L01AX03, temozolomide, Temozolomide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M01AC02, tenoxicam, Tenoxicam may decrease the antihypertensive activities of Pindolol.]
[G04CA03, terazosin, Pindolol may increase the orthostatic hypotensive activities of Terazosin.]
[D01BA02, terbinafine, The metabolism of Pindolol can be decreased when combined with Terbinafine.]
[G04BD05, terodiline, The risk or severity of bradycardia can be increased when Terodiline is combined with Pindolol.]
[C07AA16, tertatolol, Pindolol may increase the bradycardic activities of Tertatolol.]
[S01GA02, tetrahydrozoline, The therapeutic efficacy of Tetryzoline can be decreased when used in combination with Pindolol.]
[M03BX07, tetrazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Tetrazepam.]
[M03BX05, thiocolchicoside, The risk or severity of adverse effects can be increased when Pindolol is combined with Thiocolchicoside.]
[N05AB05, thiopropazate, The risk or severity of adverse effects can be increased when Pindolol is combined with Thiopropazate.]
[G04BD01, emepronium, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Emepronium.]
[N06AX14, tianeptine, The risk or severity of adverse effects can be increased when Pindolol is combined with Tianeptine.]
[C09AA02, enalapril, Enalapril may increase the hypotensive activities of Pindolol.]
[N05BA23, tofisopam, The risk or severity of adverse effects can be increased when Pindolol is combined with Tofisopam.]
[M01AG02, tolfenamic acid, Tolfenamic acid may decrease the antihypertensive activities of Pindolol.]
[N06AG03, toloxatone, Toloxatone may increase the hypotensive activities of Pindolol.]
[N06BA09, atomoxetine, The metabolism of Atomoxetine can be decreased when combined with Pindolol.]
[N03AX11, topiramate, The risk or severity of adverse effects can be increased when Topiramate is combined with Pindolol.]
[C03CA04, torsemide, Torasemide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[R01AA09, tramazoline, Tramazoline may decrease the antihypertensive activities of Pindolol.]
[C09AA10, trandolapril, Trandolapril may increase the hypotensive activities of Pindolol.]
[N05CD11, triazulenone, The risk or severity of adverse effects can be increased when Pindolol is combined with Loprazolam.]
[N05CC01, chloral hydrate, The risk or severity of adverse effects can be increased when Pindolol is combined with Chloral hydrate.]
[N05CM07, triclofos, The risk or severity of adverse effects can be increased when Pindolol is combined with Triclofos.]
[A03AB08, tridihexethyl, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Tridihexethyl.]
[R06AA10, trimethobenzamide, The risk or severity of adverse effects can be increased when Trimethobenzamide is combined with Pindolol.]
[N04AA12, tropatepine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Tropatepine.]
[R03CC11, tulobuterol, The therapeutic efficacy of Tulobuterol can be decreased when used in combination with Pindolol.]
[N01AB04, enflurane, The risk or severity of adverse effects can be increased when Enflurane is combined with Pindolol.]
[C02CA06, urapidil, Pindolol may increase the orthostatic hypotensive activities of Urapidil.]
[N05AL06, veralipride, The risk or severity of adverse effects can be increased when Pindolol is combined with Veralipride.]
[L01CA04, vinorelbine, The metabolism of Pindolol can be decreased when combined with Vinorelbine.]
[S01FB02, ephedrine, The therapeutic efficacy of Ephedrine can be decreased when used in combination with Pindolol.]
[S01GX10, epinastine, The risk or severity of adverse effects can be increased when Epinastine is combined with Pindolol.]
[N06AX16, venlafaxine, The risk or severity of serotonin syndrome can be increased when Pindolol is combined with Venlafaxine.]
[C01CX07, xamoterol, The therapeutic efficacy of Xamoterol can be decreased when used in combination with Pindolol.]
[S01GA03, xylometazoline, The risk or severity of bradycardia can be increased when Xylometazoline is combined with Pindolol.]
[C08CA12, mepirodipine, Pindolol may increase the antihypertensive activities of Barnidipine.]
[S01EA01, epinephrine, Pindolol may decrease the bronchodilatory activities of Epinephrine.]
[C09AA15, zofenopril, Pindolol may increase the hypotensive activities of Zofenopril.]
[N05CF02, zolpidem, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Zolpidem.]
[M01AB04, zomepirac, Zomepirac may decrease the antihypertensive activities of Pindolol.]
[N03AX15, zonisamide, The risk or severity of bradycardia can be increased when Zonisamide is combined with Pindolol.]
[A10AB06, insulin glulisine, human, The therapeutic efficacy of Insulin glulisine can be increased when used in combination with Pindolol.]
[N05CF01, zopiclone, The risk or severity of adverse effects can be increased when Pindolol is combined with Zopiclone.]
[N05AX11, zotepine, The risk or severity of adverse effects can be increased when Pindolol is combined with Zotepine.]
[L01XA02, carboplatin, Carboplatin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C02AC02, guanfacine, The therapeutic efficacy of Guanfacine can be decreased when used in combination with Pindolol.]
[B01AC11, iloprost, Iloprost may increase the hypotensive activities of Pindolol.]
[C01BG01, moricizine, The serum concentration of Pindolol can be increased when it is combined with Moricizine.]
[G02AB03, ergonovine, The therapeutic efficacy of Ergometrine can be decreased when used in combination with Pindolol.]
[C04AE01, ergoloid mesylates, USP, Pindolol may increase the vasoconstricting activities of Ergoloid mesylate.]
[N02CA02, ergotamine, Pindolol may increase the vasoconstricting activities of Ergotamine.]
[N03AG01, valproic acid, The risk or severity of adverse effects can be increased when Valproic acid is combined with Pindolol.]
[L03AX05, pidotimod, Pindolol may decrease the excretion rate of Pidotimod which could result in a higher serum level.]
[N05CD04, estazolam, The risk or severity of adverse effects can be increased when Pindolol is combined with Estazolam.]
[A02BC02, pantoprazole, Pantoprazole may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[H05BX01, cinacalcet, The metabolism of Pindolol can be decreased when combined with Cinacalcet.]
[G03CA03, estradiol, Estradiol may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[G03CA57, estrogens, conjugated (USP), Conjugated estrogens may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J04AK02, ethambutol, Ethambutol may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C10AA04, fluvastatin, The metabolism of Fluvastatin can be decreased when combined with Pindolol.]
[V08CA03, gadodiamide, Gadodiamide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C01CA15, gepefrine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Gepefrine.]
[N05CM08, ethchlorvynol, The risk or severity of adverse effects can be increased when Ethchlorvynol is combined with Pindolol.]
[V03AF05, amifostine, Pindolol may increase the hypotensive activities of Amifostine.]
[C01BD05, ibutilide, Ibutilide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N04AA05, profenamine, Profenamine may increase the bradycardic activities of Pindolol.]
[N03AD01, ethosuximide, The risk or severity of bradycardia can be increased when Ethosuximide is combined with Pindolol.]
[N03AB01, ethotoin, The risk or severity of adverse effects can be increased when Ethotoin is combined with Pindolol.]
[M01AC06, meloxicam, Meloxicam may decrease the antihypertensive activities of Pindolol.]
[S01XA06, ethylmorphine, The risk or severity of adverse effects can be increased when Pindolol is combined with Ethylmorphine.]
[C01CA01, etilefrine, The therapeutic efficacy of Etilefrine can be decreased when used in combination with Pindolol.]
[N01AX07, etomidate, The therapeutic efficacy of Etomidate can be decreased when used in combination with Pindolol.]
[N05AE03, sertindole, The risk or severity of adverse effects can be increased when Pindolol is combined with Sertindole.]
[L04AD02, tacrolimus, The risk or severity of hyperkalemia can be increased when Tacrolimus is combined with Pindolol.]
[A02BA04, nizatidine, Nizatidine may increase the bradycardic activities of Pindolol.]
[R06AX11, astemizole, The metabolism of Astemizole can be decreased when combined with Pindolol.]
[R06AX12, terfenadine, The metabolism of Pindolol can be decreased when combined with Terfenadine.]
[P01AX07, trimetrexate, Pindolol may decrease the excretion rate of Trimetrexate which could result in a higher serum level.]
[N06AX12, bupropion, The metabolism of Pindolol can be decreased when combined with Bupropion.]
[N06AB08, fluvoxamine, The metabolism of Pindolol can be decreased when combined with Fluvoxamine.]
[C01BC08, encainide, The metabolism of Encainide can be decreased when combined with Pindolol.]
[L02AE02, leuprolide, Leuprolide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M01CB01, gold sodium thiomalate, Pindolol may decrease the excretion rate of Sodium aurothiomalate which could result in a higher serum level.]
[B05AA05, dextran, Pindolol may decrease the excretion rate of Dextran which could result in a higher serum level.]
[V03AF02, dexrazoxane, Dexrazoxane may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[A16AA01, levocarnitine, Levocarnitine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C08CA02, felodipine, The risk or severity of bradycardia can be increased when Felodipine is combined with Pindolol.]
[C08EA01, fendiline, The risk or severity of bradycardia can be increased when Fendiline is combined with Pindolol.]
[N03AX26, fenfluramine, The therapeutic efficacy of Fenfluramine can be decreased when used in combination with Pindolol.]
[M01AE04, fenoprofen, Fenoprofen may decrease the antihypertensive activities of Pindolol.]
[R03CC04, fenoterol, Pindolol may decrease the bronchodilatory activities of Fenoterol.]
[N02AB03, fentanyl, The risk or severity of adverse effects can be increased when Fentanyl is combined with Pindolol.]
[R03CC02, albuterol, Pindolol may decrease the bronchodilatory activities of Salbutamol.]
[L01BB06, clofarabine, The risk or severity of adverse effects can be increased when Clofarabine is combined with Pindolol.]
[N07AX03, cevimeline, The risk or severity of adverse effects can be increased when Pindolol is combined with Cevimeline.]
[G04BD02, flavoxate, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Flavoxate.]
[C01BC04, flecainide, The metabolism of Flecainide can be decreased when combined with Pindolol.]
[N02BG04, floctafenine, The risk or severity of adverse effects can be increased when Pindolol is combined with Floctafenine.]
[J02AC01, fluconazole, The risk or severity of hyperkalemia can be increased when Fluconazole is combined with Pindolol.]
[J02AX01, flucytosine, Pindolol may decrease the excretion rate of Flucytosine which could result in a higher serum level.]
[V03AB25, flumazenil, Pindolol may decrease the excretion rate of Flumazenil which could result in a higher serum level.]
[N07CA03, flunarizine, The risk or severity of bradycardia can be increased when Flunarizine is combined with Pindolol.]
[N05CD03, flunitrazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Flunitrazepam.]
[N06AA14, melitracen, The risk or severity of adverse effects can be increased when Pindolol is combined with Melitracen.]
[V03AZ01, ethanol, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Ethanol.]
[L01BC09, floxuridine, Floxuridine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N06AB03, fluoxetine, The serum concentration of Pindolol can be increased when it is combined with Fluoxetine.]
[N05AF01, flupenthixol, Pindolol may increase the orthostatic hypotensive activities of Flupentixol.]
[N05AB02, fluphenazine, The serum concentration of Pindolol can be increased when it is combined with Fluphenazine.]
[N05CD01, flurazepam, The risk or severity of adverse effects can be increased when Flurazepam is combined with Pindolol.]
[S01BC04, flurbiprofen, Flurbiprofen may decrease the antihypertensive activities of Pindolol.]
[N05AG01, fluspirilene, The risk or severity of bradycardia can be increased when Fluspirilene is combined with Pindolol.]
[L02BB01, flutamide, Flutamide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[V04CX02, folic acid, Folic acid may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S02AA17, fosfomycin, Fosfomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S01AA07, framycetin, Framycetin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L01BC03, tegafur, Pindolol may decrease the excretion rate of Tegafur which could result in a higher serum level.]
[N06BX17, adrafinil, The therapeutic efficacy of Adrafinil can be decreased when used in combination with Pindolol.]
[M03AA01, alcuronium, The risk or severity of adverse effects can be increased when Pindolol is combined with Alcuronium.]
[G01AX06, furazolidone, Furazolidone may increase the hypotensive activities of Pindolol.]
[J05AE10, darunavir, The metabolism of Pindolol can be decreased when combined with Darunavir.]
[C03CA01, furosemide, Furosemide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05CF04, eszopiclone, The risk or severity of CNS depression can be increased when Pindolol is combined with Eszopiclone.]
[N05AL05, amisulpride, The risk or severity of adverse effects can be increased when Pindolol is combined with Amisulpride.]
[N06DA04, galantamine, Galantamine may increase the bradycardic activities of Pindolol.]
[M03AC02, gallamine, The risk or severity of adverse effects can be increased when Pindolol is combined with Gallamine.]
[C08DA02, gallopamil, The risk or severity of bradycardia can be increased when Gallopamil is combined with Pindolol.]
[S01AD09, ganciclovir, Pindolol may decrease the excretion rate of Ganciclovir which could result in a higher serum level.]
[N03AA04, barbexaclone, Barbexaclone may increase the hypotensive activities of Pindolol.]
[N06AX08, bifemelane, The risk or severity of adverse effects can be increased when Pindolol is combined with Bifemelane.]
[C10AB04, gemfibrozil, Pindolol may decrease the excretion rate of Gemfibrozil which could result in a higher serum level.]
[J01XA03, telavancin, Pindolol may decrease the excretion rate of Telavancin which could result in a higher serum level.]
[N04BC06, cabergoline, Pindolol may increase the vasoconstricting activities of Cabergoline.]
[C01CA21, cafedrine, The risk or severity of adverse effects can be increased when Pindolol is combined with Cafedrine.]
[A10BJ02, liraglutide, The therapeutic efficacy of Liraglutide can be increased when used in combination with Pindolol.]
[A12AA13, calcium citrate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium citrate.]
[A12AA10, calcium gluceptate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium glucoheptonate.]
[A12AA05, calcium lactate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium lactate.]
[A12AA30, calcium levulinate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium levulinate.]
[N03AD03, methsuximide, The risk or severity of bradycardia can be increased when Methsuximide is combined with Pindolol.]
[N01AH02, alfentanil, The risk or severity of adverse effects can be increased when Alfentanil is combined with Pindolol.]
[A10BB01, glyburide, The therapeutic efficacy of Glyburide can be increased when used in combination with Pindolol.]
[A10BB09, gliclazide, The therapeutic efficacy of Gliclazide can be increased when used in combination with Pindolol.]
[A10BB07, glipizide, The therapeutic efficacy of Glipizide can be increased when used in combination with Pindolol.]
[H04AA01, glucagon, The therapeutic efficacy of Pindolol can be decreased when used in combination with Glucagon.]
[N05CM18, dexmedetomidine, The therapeutic efficacy of Dexmedetomidine can be decreased when used in combination with Pindolol.]
[N05CE01, glutethimide, The risk or severity of adverse effects can be increased when Pindolol is combined with Glutethimide.]
[C05AE01, nitroglycerin, Nitroglycerin may increase the hypotensive activities of Pindolol.]
[C02CA04, doxazosin, Pindolol may increase the orthostatic hypotensive activities of Doxazosin.]
[H01AB01, thyrotropin alfa, The therapeutic efficacy of Thyrotropin alfa can be decreased when used in combination with Pindolol.]
[L01EX02, sorafenib, Sorafenib may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C07AB09, esmolol, Esmolol may increase the hypotensive activities of Pindolol.]
[M01CB04, aurothioglucose, Pindolol may decrease the excretion rate of Aurothioglucose which could result in a higher serum level.]
[S01LA03, pegaptanib, Pindolol may decrease the excretion rate of Pegaptanib which could result in a higher serum level.]
[B01AA12, fluindione, The risk or severity of adverse effects can be increased when Pindolol is combined with Fluindione.]
[C09AA09, fosinopril, Fosinopril may increase the hypotensive activities of Pindolol.]
[S01EX01, guanethidine, Guanethidine may increase the hypotensive activities of Pindolol.]
[L02AE03, goserelin, Goserelin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[P01BX01, halofantrine, The metabolism of Pindolol can be decreased when combined with Halofantrine.]
[N05AD01, haloperidol, The risk or severity of CNS depression can be increased when Haloperidol is combined with Pindolol.]
[N01AB01, halothane, The risk or severity of adverse effects can be increased when Pindolol is combined with Halothane.]
[N05AH04, quetiapine, Quetiapine may increase the hypotensive activities of Pindolol.]
[N06BX13, idebenone, Pindolol may decrease the excretion rate of Idebenone which could result in a higher serum level.]
[A10AD05, insulin aspart, human, The therapeutic efficacy of Insulin aspart can be increased when used in combination with Pindolol.]
[N02CX03, iprazochrome, The risk or severity of adverse effects can be increased when Pindolol is combined with Iprazochrome.]
[N05CA21, allobarbital, The risk or severity of adverse effects can be increased when Pindolol is combined with Allobarbital.]
[M04AA01, allopurinol, Allopurinol may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C09CA01, losartan, Losartan may increase the hypotensive activities of Pindolol.]
[S01XA14, heparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Heparin.]
[G03DC01, allylestrenol, Pindolol may decrease the excretion rate of Allylestrenol which could result in a higher serum level.]
[A07EC02, mesalamine, Mesalazine may decrease the antihypertensive activities of Pindolol.]
[C01CE02, milrinone, Milrinone may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05CA16, hexobarbital, Hexobarbital may increase the hypotensive activities of Pindolol.]
[R03CC05, hexoprenaline, Pindolol may decrease the bronchodilatory activities of Hexoprenaline.]
[J05AG01, nevirapine, The metabolism of Pindolol can be decreased when combined with Nevirapine.]
[C08CA10, nilvadipine, The risk or severity of bradycardia can be increased when Nilvadipine is combined with Pindolol.]
[M02AA26, nimesulide, Nimesulide may decrease the antihypertensive activities of Pindolol.]
[C09AA04, perindopril, Perindopril may increase the hypotensive activities of Pindolol.]
[C02DB02, hydralazine, Pindolol may increase the hypotensive activities of Hydralazine.]
[R05DA03, hydrocodone, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Hydrocodone.]
[C03AA02, hydroflumethiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Hydroflumethiazide.]
[B05XA17, potassium acetate, Potassium acetate may increase the hyperkalemic activities of Pindolol.]
[S01XA07, aluminum potassium sulfate, Potassium alum may increase the hyperkalemic activities of Pindolol.]
[A12BA02, potassium citrate, Potassium citrate may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB33, hydroxocobalamin, Hydroxocobalamin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[G04BD06, propiverine, Pindolol may increase the orthostatic hypotensive activities of Propiverine.]
[P01BA02, hydroxychloroquine, The risk or severity of QTc prolongation can be decreased when Hydroxychloroquine is combined with Pindolol.]
[N05AX07, prothipendyl, The risk or severity of adverse effects can be increased when Pindolol is combined with Prothipendyl.]
[B05AA07, hetastarch, Pindolol may decrease the excretion rate of Hydroxyethyl Starch which could result in a higher serum level.]
[N05BB01, hydroxyzine, Hydroxyzine may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[C02AC06, rilmenidine, The therapeutic efficacy of Rilmenidine can be decreased when used in combination with Pindolol.]
[R02AX02, ibuprofen, Ibuprofen may decrease the antihypertensive activities of Pindolol.]
[B05XA08, sodium acetate, Pindolol may decrease the excretion rate of Sodium acetate which could result in a higher serum level.]
[L01DB06, idarubicin, The metabolism of Idarubicin can be decreased when combined with Pindolol.]
[L01AA06, ifosfamide, Pindolol may decrease the excretion rate of Ifosfamide which could result in a higher serum level.]
[N01AH03, sufentanil, The risk or severity of adverse effects can be increased when Sufentanil is combined with Pindolol.]
[N06AA02, imipramine, The metabolism of Pindolol can be decreased when combined with Imipramine.]
[L01CD01, paclitaxel, The risk or severity of adverse effects can be increased when Pindolol is combined with Paclitaxel.]
[R01AD07, tixocortol, Pindolol may decrease the excretion rate of Tixocortol which could result in a higher serum level.]
[M03BX02, tizanidine, The therapeutic efficacy of Tizanidine can be decreased when used in combination with Pindolol.]
[L01CE01, topotecan, Pindolol may decrease the excretion rate of Topotecan which could result in a higher serum level.]
[C03BA11, indapamide, The therapeutic efficacy of Indapamide can be increased when used in combination with Pindolol.]
[S01BC01, indomethacin, Indomethacin may decrease the antihypertensive activities of Pindolol.]
[C02CA02, indoramin, Pindolol may increase the orthostatic hypotensive activities of Indoramin.]
[A11HA07, inositol, Pindolol may decrease the excretion rate of Inositol which could result in a higher serum level.]
[N06AX17, milnacipran, The risk or severity of adverse effects can be increased when Pindolol is combined with Milnacipran.]
[A03AA30, piperidolate, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Piperidolate.]
[S01XA28, varenicline, The risk or severity of adverse effects can be increased when Pindolol is combined with Varenicline.]
[N01BB08, articaine, The risk or severity of adverse effects can be increased when Pindolol is combined with Articaine.]
[A10BH01, sitagliptin, The therapeutic efficacy of Sitagliptin can be increased when used in combination with Pindolol.]
[N05BA12, alprazolam, The risk or severity of adverse effects can be increased when Alprazolam is combined with Pindolol.]
[N05CH02, ramelteon, The risk or severity of adverse effects can be increased when Pindolol is combined with Ramelteon.]
[R06AE01, buclizine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Buclizine.]
[A10BH02, vildagliptin, The therapeutic efficacy of Vildagliptin can be increased when used in combination with Pindolol.]
[C10AA06, cerivastatin, The metabolism of Pindolol can be decreased when combined with Cerivastatin.]
[C07AA01, alprenolol, The risk or severity of adverse effects can be increased when Alprenolol is combined with Pindolol.]
[C03BA02, quinethazone, Quinethazone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[V03AB01, ipecac, Pindolol may decrease the excretion rate of Ipecac which could result in a higher serum level.]
[N06AA13, iprindole, The risk or severity of adverse effects can be increased when Pindolol is combined with Iprindole.]
[N06AF05, iproniazid, Iproniazid may increase the hypotensive activities of Pindolol.]
[N05AA07, chlorproethazine, The serum concentration of Pindolol can be increased when it is combined with Chlorproethazine.]
[N06AF01, isocarboxazid, Isocarboxazid may increase the hypotensive activities of Pindolol.]
[S01EC03, dorzolamide, Dorzolamide may increase the hypotensive activities of Pindolol.]
[R03CC06, isoetharine, Pindolol may decrease the bronchodilatory activities of Isoetharine.]
[C09AA16, imidapril, Pindolol may increase the hypotensive activities of Imidapril.]
[N01AB06, isoflurane, The risk or severity of adverse effects can be increased when Isoflurane is combined with Pindolol.]
[S01EB07, isoflurophate, Isoflurophate may increase the bradycardic activities of Pindolol.]
[N04BX02, entacapone, The risk or severity of adverse effects can be increased when Entacapone is combined with Pindolol.]
[J04AC01, isoniazid, The risk or severity of serotonin syndrome can be increased when Isoniazid is combined with Pindolol.]
[J05AX05, inosine pranobex, Pindolol may decrease the excretion rate of Inosine pranobex which could result in a higher serum level.]
[R03CB01, isoproterenol, Pindolol may decrease the bronchodilatory activities of Isoprenaline.]
[A10BJ01, exenatide, The therapeutic efficacy of Exenatide can be increased when used in combination with Pindolol.]
[C01DA14, isosorbide mononitrate, Pindolol may increase the vasodilatory activities of Isosorbide mononitrate.]
[C05AE02, isosorbide dinitrate, The risk or severity of adverse effects can be increased when Isosorbide dinitrate is combined with Pindolol.]
[D10BA01, isotretinoin, Pindolol may decrease the excretion rate of Isotretinoin which could result in a higher serum level.]
[C04AA01, isoxsuprine, The therapeutic efficacy of Isoxsuprine can be decreased when used in combination with Pindolol.]
[N06AX18, reboxetine, The risk or severity of adverse effects can be increased when Reboxetine is combined with Pindolol.]
[S01AA24, kanamycin, Pindolol may decrease the excretion rate of Kanamycin which could result in a higher serum level.]
[L04AC07, tocilizumab, The metabolism of Pindolol can be increased when combined with Tocilizumab.]
[N01AX03, ketamine, Ketamine may increase the bradycardic activities of Pindolol.]
[C02KD01, ketanserin, The risk or severity of adverse effects can be increased when Pindolol is combined with Ketanserin.]
[B01AC22, prasugrel, Pindolol may decrease the excretion rate of Prasugrel which could result in a higher serum level.]
[J02AB02, ketoconazole, The metabolism of Pindolol can be decreased when combined with Ketoconazole.]
[N05AH03, olanzapine, Pindolol may increase the orthostatic hypotensive activities of Olanzapine.]
[M02AA10, ketoprofen, Ketoprofen may decrease the antihypertensive activities of Pindolol.]
[L04AA24, abatacept, The metabolism of Pindolol can be increased when combined with Abatacept.]
[C01CA22, arbutamine, Pindolol may decrease the bronchodilatory activities of Arbutamine.]
[N04BC09, rotigotine, Pindolol may increase the sedative activities of Rotigotine.]
[D10AX03, azelaic acid, Azelaic acid may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[M01AE11, tiaprofenic acid, Tiaprofenic acid may decrease the antihypertensive activities of Pindolol.]
[C07AG01, labetalol, Pindolol may increase the orthostatic hypotensive activities of Labetalol.]
[N04BB01, amantadine, The risk or severity of serotonin syndrome can be increased when Amantadine is combined with Pindolol.]
[C02AA05, deserpidine, Deserpidine may increase the hypotensive activities of Pindolol.]
[N07AA30, ambenonium, Ambenonium may increase the bradycardic activities of Pindolol.]
[A06AX03, lubiprostone, Pindolol may decrease the excretion rate of Lubiprostone which could result in a higher serum level.]
[N03AX18, lacosamide, The risk or severity of adverse effects can be increased when Pindolol is combined with Lacosamide.]
[C03CC01, ethacrynic acid, Etacrynic acid may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N04BA01, levodopa, The risk or severity of hypotension and orthostatic hypotension can be increased when Pindolol is combined with Levodopa.]
[S02DA01, lidocaine, The serum concentration of Lidocaine can be increased when it is combined with Pindolol.]
[C08EX01, lidoflazine, The risk or severity of bradycardia can be increased when Lidoflazine is combined with Pindolol.]
[S01AA21, amikacin, Pindolol may decrease the excretion rate of Amikacin which could result in a higher serum level.]
[C03DB01, amiloride, Amiloride may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N02CA07, lisuride, Pindolol may increase the vasoconstricting activities of Lisuride.]
[N06AA07, lofepramine, The risk or severity of adverse effects can be increased when Pindolol is combined with Lofepramine.]
[A07DA03, loperamide, The risk or severity of bradycardia can be increased when Loperamide is combined with Pindolol.]
[A12AA11, calcium pangamate, The therapeutic efficacy of Pindolol can be decreased when used in combination with Calcium pangamate.]
[N05BA06, lorazepam, The risk or severity of adverse effects can be increased when Lorazepam is combined with Pindolol.]
[C10AA02, lovastatin, The metabolism of Pindolol can be decreased when combined with Lovastatin.]
[N05AH01, loxapine, The risk or severity of adverse effects can be increased when Loxapine is combined with Pindolol.]
[L01EG01, temsirolimus, The metabolism of Pindolol can be decreased when combined with Temsirolimus.]
[B05XA11, magnesium chloride, Pindolol may decrease the excretion rate of Magnesium chloride which could result in a higher serum level.]
[G04BX01, magnesium hydroxide, Pindolol may decrease the excretion rate of Magnesium hydroxide which could result in a higher serum level.]
[V04CC02, magnesium sulfate, The therapeutic efficacy of Pindolol can be increased when used in combination with Magnesium sulfate.]
[L01BA05, pralatrexate, Pindolol may decrease the excretion rate of Pralatrexate which could result in a higher serum level.]
[V04CX04, mannitol, Mannitol may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N06AA21, maprotiline, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Maprotiline.]
[A08AA05, mazindol, The risk or severity of adverse effects can be increased when Mazindol is combined with Pindolol.]
[C02BB01, mecamylamine, Mecamylamine may increase the hypotensive activities of Pindolol.]
[L01AA05, mechlorethamine, Mechlorethamine may increase the bradycardic activities of Pindolol.]
[R06AE05, meclizine, The risk or severity of adverse effects can be increased when Meclizine is combined with Pindolol.]
[M02AA18, meclofenamic acid, Meclofenamic acid may decrease the antihypertensive activities of Pindolol.]
[N05BA03, medazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Medazepam.]
[C01AA08, medigoxin, Pindolol may increase the bradycardic activities of Metildigoxin.]
[P01BC02, mefloquine, The risk or severity of QTc prolongation can be decreased when Mefloquine is combined with Pindolol.]
[C03BA05, mefruside, Mefruside may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[B01AB06, nadroparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Nadroparin.]
[B01AB05, enoxaparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Enoxaparin.]
[B01AB04, dalteparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Dalteparin.]
[N05CH01, melatonin, The risk or severity of adverse effects can be increased when Pindolol is combined with Melatonin.]
[N06DX01, memantine, Memantine may increase the bradycardic activities of Pindolol.]
[N02AB02, meperidine, The risk or severity of adverse effects can be increased when Meperidine is combined with Pindolol.]
[C01CA11, mephentermine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Mephentermine.]
[N03AB04, mephenytoin, The risk or severity of adverse effects can be increased when Mephenytoin is combined with Pindolol.]
[N03AA01, mephobarbital, Methylphenobarbital may increase the hypotensive activities of Pindolol.]
[N01BB03, mepivacaine, The serum concentration of Mepivacaine can be increased when it is combined with Pindolol.]
[N05BC01, meprobamate, The risk or severity of adverse effects can be increased when Meprobamate is combined with Pindolol.]
[N02AX05, meptazinol, The risk or severity of adverse effects can be increased when Pindolol is combined with Meptazinol.]
[G04BX16, tiopronin, Pindolol may decrease the excretion rate of Tiopronin which could result in a higher serum level.]
[C03BC01, mersalyl, Mersalyl may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[N05AC03, mesoridazine, The serum concentration of Pindolol can be increased when it is combined with Mesoridazine.]
[N05AX13, paliperidone, Pindolol may increase the orthostatic hypotensive activities of Paliperidone.]
[C01CA09, metaraminol, The therapeutic efficacy of Metaraminol can be decreased when used in combination with Pindolol.]
[A10BA02, metformin, The therapeutic efficacy of Metformin can be increased when used in combination with Pindolol.]
[A04AA04, dolasetron, The risk or severity of adverse effects can be increased when Dolasetron is combined with Pindolol.]
[H01CB03, lanreotide, Pindolol may increase the bradycardic activities of Lanreotide.]
[N07BC02, methadone, The risk or severity of adverse effects can be increased when Methadone is combined with Pindolol.]
[N06BA03, methamphetamine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Metamfetamine.]
[A03AB07, methantheline, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Methantheline.]
[R06AC05, methapyrilene, The risk or severity of adverse effects can be increased when Pindolol is combined with Methapyrilene.]
[N05CM01, methaqualone, The risk or severity of adverse effects can be increased when Pindolol is combined with Methaqualone.]
[J05AF05, lamivudine, Lamivudine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N03AA30, metharbital, The risk or severity of adverse effects can be increased when Metharbital is combined with Pindolol.]
[S01EC05, methazolamide, Methazolamide may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[G02CB05, metergoline, Pindolol may increase the vasoconstricting activities of Metergoline.]
[H03BB02, methimazole, The excretion of Pindolol can be decreased when combined with Methimazole.]
[L01BA04, pemetrexed, Pindolol may decrease the excretion rate of Pemetrexed which could result in a higher serum level.]
[M03BA03, methocarbamol, The risk or severity of adverse effects can be increased when Methocarbamol is combined with Pindolol.]
[N05CA15, methohexital, Methohexital may increase the hypotensive activities of Pindolol.]
[A11HA02, pyridoxine, Pyridoxine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N02BG08, ziconotide, The risk or severity of bradycardia can be increased when Ziconotide is combined with Pindolol.]
[L04AX03, methotrexate, Methotrexate may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N05AA02, methotrimeprazine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Methotrimeprazine.]
[C01CA10, methoxamine, The therapeutic efficacy of Methoxamine can be decreased when used in combination with Pindolol.]
[D05BA02, methoxsalen, Methoxsalen may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N02BG09, methoxyflurane, The risk or severity of adverse effects can be increased when Pindolol is combined with Methoxyflurane.]
[C03AA08, methyclothiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Methyclothiazide.]
[C02AB01, methyldopa, The therapeutic efficacy of Methyldopa can be decreased when used in combination with Pindolol.]
[V04CG05, methylene blue, Pindolol may increase the serotonergic activities of Methylene blue.]
[G02AB01, methylergonovine, Pindolol may increase the vasoconstricting activities of Methylergometrine.]
[R03DA05, aminophylline, The risk or severity of adverse effects can be increased when Pindolol is combined with Aminophylline.]
[N06BA04, methylphenidate, Methylphenidate may decrease the antihypertensive activities of Pindolol.]
[N03AF03, rufinamide, The risk or severity of adverse effects can be increased when Rufinamide is combined with Pindolol.]
[G03EK01, methyltestosterone, Pindolol may decrease the excretion rate of Methyltestosterone which could result in a higher serum level.]
[N05CE02, methyprylon, The risk or severity of adverse effects can be increased when Pindolol is combined with Methyprylon.]
[N02CA04, methysergide, Pindolol may increase the vasoconstricting activities of Methysergide.]
[A03FA01, metoclopramide, The risk or severity of sedation can be increased when Metoclopramide is combined with Pindolol.]
[C03BA08, metolazone, Metolazone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
[C07AB02, metoprolol, The metabolism of Pindolol can be decreased when combined with Metoprolol.]
[V04CD01, metyrapone, Pindolol may decrease the excretion rate of Metyrapone which could result in a higher serum level.]
[C01BB02, mexiletine, The metabolism of Mexiletine can be decreased when combined with Pindolol.]
[N06AX03, mianserin, The risk or severity of adverse effects can be increased when Pindolol is combined with Mianserin.]
[S02AA13, miconazole, The metabolism of Pindolol can be decreased when combined with Miconazole.]
[N02BB03, aminopyrine, Aminophenazone may decrease the antihypertensive activities of Pindolol.]
[B01AB07, parnaparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Parnaparin.]
[N05CD08, midazolam, The risk or severity of adverse effects can be increased when Midazolam is combined with Pindolol.]
[C01CA17, midodrine, The therapeutic efficacy of Midodrine can be decreased when used in combination with Pindolol.]
[G03XB01, mifepristone, The therapeutic efficacy of Mifepristone can be increased when used in combination with Pindolol.]
[B01AB10, tinzaparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Tinzaparin.]
[J05AH01, zanamivir, Zanamivir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C09CA03, valsartan, Valsartan may increase the hypotensive activities of Pindolol.]
[J01AA08, minocycline, Minocycline may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[D11AX01, minoxidil, Minoxidil may increase the hypotensive activities of Pindolol.]
[N06BA12, lisdexamfetamine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Lisdexamfetamine.]
[N05AE02, molindone, The risk or severity of adverse effects can be increased when Pindolol is combined with Molindone.]
[L03AC01, aldesleukin, The risk or severity of adverse effects can be increased when Aldesleukin is combined with Pindolol.]
[C01DX12, molsidomine, Molsidomine may increase the hypotensive activities of Pindolol.]
[C01BD01, amiodarone, The therapeutic efficacy of Pindolol can be increased when used in combination with Amiodarone.]
[N06AA09, amitriptyline, The metabolism of Amitriptyline can be decreased when combined with Pindolol.]
[N02AA01, morphine, The risk or severity of adverse effects can be increased when Morphine is combined with Pindolol.]
[A04AA05, palonosetron, The risk or severity of adverse effects can be increased when Palonosetron is combined with Pindolol.]
[J01DD06, moxalactam, Latamoxef may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L04AB05, certolizumab pegol, The metabolism of Pindolol can be increased when combined with Certolizumab pegol.]
[G04BA01, ammonium chloride, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Ammonium chloride.]
[L01EX03, pazopanib, The metabolism of Pazopanib can be decreased when combined with Pindolol.]
[L04AA06, mycophenolic acid, Pindolol may decrease the excretion rate of Mycophenolic acid which could result in a higher serum level.]
[M03AC03, vecuronium, The risk or severity of adverse effects can be increased when Pindolol is combined with Vecuronium.]
[N05CA02, amobarbital, Amobarbital may increase the hypotensive activities of Pindolol.]
[P01BA06, amodiaquine, The risk or severity of QTc prolongation can be decreased when Amodiaquine is combined with Pindolol.]
[G04CA04, silodosin, The risk or severity of orthostatic hypotension and dizziness can be increased when Pindolol is combined with Silodosin.]
[R03BB01, ipratropium bromide, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Ipratropium.]
[N06AA17, amoxapine, The metabolism of Amoxapine can be decreased when combined with Pindolol.]
[N03AB05, fosphenytoin, The risk or severity of adverse effects can be increased when Pindolol is combined with Fosphenytoin.]
[C07AA12, nadolol, Pindolol may increase the hypotensive activities of Nadolol.]
[J01CA04, amoxicillin, Pindolol may decrease the excretion rate of Amoxicillin which could result in a higher serum level.]
[N04BC04, ropinirole, Pindolol may increase the sedative activities of Ropinirole.]
[C04AX21, nafronyl, The risk or severity of adverse effects can be increased when Pindolol is combined with Naftidrofuryl.]
[N02AF02, nalbuphine, The risk or severity of adverse effects can be increased when Nalbuphine is combined with Pindolol.]
[V03AB15, naloxone, Pindolol may decrease the excretion rate of Naloxone which could result in a higher serum level.]
[N07BB04, naltrexone, The risk or severity of serotonin syndrome can be increased when Naltrexone is combined with Pindolol.]
[L04AC03, anakinra, The metabolism of Pindolol can be increased when combined with Anakinra.]
[S01GA01, naphazoline, The therapeutic efficacy of Naphazoline can be decreased when used in combination with Pindolol.]
[N06BA01, amphetamine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Amphetamine.]
[M02AA12, naproxen, Naproxen may decrease the antihypertensive activities of Pindolol.]
[A10BG01, troglitazone, The therapeutic efficacy of Troglitazone can be increased when used in combination with Pindolol.]
[N06AX21, duloxetine, The risk or severity of orthostatic hypotension and syncope can be increased when Pindolol is combined with Duloxetine.]
[N04BX01, tolcapone, The risk or severity of adverse effects can be increased when Tolcapone is combined with Pindolol.]
[S03AA01, neomycin, Pindolol may decrease the excretion rate of Neomycin which could result in a higher serum level.]
[N01AH06, remifentanil, The risk or severity of adverse effects can be increased when Remifentanil is combined with Pindolol.]
[A10BX02, repaglinide, The therapeutic efficacy of Repaglinide can be increased when used in combination with Pindolol.]
[C01CX08, levosimendan, The risk or severity of adverse effects can be increased when Levosimendan is combined with Pindolol.]
[B01AC17, tirofiban, Tirofiban may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[S01EB06, neostigmine, Neostigmine may increase the bradycardic activities of Pindolol.]
[N05AX14, iloperidone, Pindolol may increase the orthostatic hypotensive activities of Iloperidone.]
[J02AA01, amphotericin B, The risk or severity of adverse effects can be increased when Amphotericin B is combined with Pindolol.]
[S01AA19, ampicillin, Ampicillin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[L03AX16, plerixafor, Pindolol may decrease the excretion rate of Plerixafor which could result in a higher serum level.]
[S01AA23, netilmicin, Pindolol may decrease the excretion rate of Netilmicin which could result in a higher serum level.]
[N06AX23, desvenlafaxine, The risk or severity of adverse effects can be increased when Pindolol is combined with Desvenlafaxine.]
[C09CA07, telmisartan, Pindolol may increase the hypotensive activities of Telmisartan.]
[J05AB11, valacyclovir, Valaciclovir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C01CE01, inamrinone, Pindolol may decrease the excretion rate of Amrinone which could result in a higher serum level.]
[C10AD02, niacin, The metabolism of Pindolol can be decreased when combined with Niacin.]
[N06AF02, nialamide, Nialamide may increase the hypotensive activities of Pindolol.]
[C08CA04, nicardipine, The risk or severity of bradycardia can be increased when Nicardipine is combined with Pindolol.]
[C04AE02, nicergoline, Pindolol may increase the vasoconstricting activities of Nicergoline.]
[N07BA01, nicotine, The risk or severity of adverse effects can be increased when Pindolol is combined with Nicotine.]
[C08CA05, nifedipine, The risk or severity of congestive heart failure and hypotension can be increased when Nifedipine is combined with Pindolol.]
[M02AA17, niflumic acid, Niflumic acid may decrease the antihypertensive activities of Pindolol.]
[V03AB22, amyl nitrite, The risk or severity of adverse effects can be increased when Pindolol is combined with Amyl Nitrite.]
[C08CA06, nimodipine, The risk or severity of bradycardia can be increased when Nimodipine is combined with Pindolol.]
[C08CA07, nisoldipine, The risk or severity of bradycardia can be increased when Nisoldipine is combined with Pindolol.]
[N05CD02, nitrazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Nitrazepam.]
[C08CA08, nitrendipine, The risk or severity of bradycardia can be increased when Nitrendipine is combined with Pindolol.]
[R07AX01, nitric oxide, The risk or severity of adverse effects can be increased when Nitric Oxide is combined with Pindolol.]
[J01XE01, nitrofurantoin, The risk or severity of hyperkalemia can be increased when Nitrofurantoin is combined with Pindolol.]
[N05CF03, zaleplon, The risk or severity of adverse effects can be increased when Pindolol is combined with Zaleplon.]
[N04BC05, pramipexole, Pindolol may increase the sedative activities of Pramipexole.]
[C02DD01, nitroprusside, Nitroprusside may increase the hypotensive activities of Pindolol.]
[N01AX13, nitrous oxide, The risk or severity of adverse effects can be increased when Pindolol is combined with Nitrous oxide.]
[N06AX04, nomifensine, The risk or severity of adverse effects can be increased when Pindolol is combined with Nomifensine.]
[C01CA03, norepinephrine, Pindolol may decrease the bronchodilatory activities of Norepinephrine.]
[C02KX01, bosentan, Bosentan may increase the hypotensive activities of Pindolol.]
[N06AA10, nortriptyline, The metabolism of Nortriptyline can be decreased when combined with Pindolol.]
[G02CA02, nylidrin, The risk or severity of bradycardia can be increased when Nylidrin is combined with Pindolol.]
[B01AB08, reviparin, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Reviparin.]
[H01CB02, octreotide, The serum concentration of the active metabolites of Octreotide can be increased when Octreotide is used in combination with Pindolol.]
[L04AC04, rilonacept, The metabolism of Pindolol can be increased when combined with Rilonacept.]
[A02BC01, omeprazole, The metabolism of Pindolol can be decreased when combined with Omeprazole.]
[N06AA05, opipramol, The risk or severity of adverse effects can be increased when Pindolol is combined with Opipramol.]
[N02AA02, opium, The risk or severity of adverse effects can be increased when Pindolol is combined with Opium.]
[R03CB03, metaproterenol, Pindolol may decrease the bronchodilatory activities of Orciprenaline.]
[G04CA02, tamsulosin, Pindolol may increase the orthostatic hypotensive activities of Tamsulosin.]
[C01AC01, ouabain, Pindolol may increase the bradycardic activities of Ouabain.]
[J01CF04, oxacillin, Oxacillin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[P02BA02, oxamniquine, The metabolism of Pindolol can be decreased when combined with Oxamniquine.]
[N05BA04, oxazepam, The risk or severity of adverse effects can be increased when Oxazepam is combined with Pindolol.]
[C07AA02, oxprenolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxprenolol.]
[N02AA05, oxycodone, The risk or severity of adverse effects can be increased when Oxycodone is combined with Pindolol.]
[C01DX03, oxyfedrine, The therapeutic efficacy of Oxyfedrine can be decreased when used in combination with Pindolol.]
[S01GA04, oxymetazoline, The risk or severity of cardiovascular complications can be increased when Pindolol is combined with Oxymetazoline.]
[N02AA11, oxymorphone, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxymorphone.]
[N05AE01, oxypertine, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxypertine.]
[S01BC02, oxyphenbutazone, Oxyphenbutazone may decrease the antihypertensive activities of Pindolol.]
[A03AB03, oxyphenonium, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Oxyphenonium.]
[N05AH05, asenapine, Pindolol may increase the orthostatic hypotensive activities of Asenapine.]
[B01AB09, danaparoid, The risk or severity of hyperkalemia can be increased when Pindolol is combined with Danaparoid.]
[N02AX06, tapentadol, Tapentadol may increase the central nervous system depressant (CNS depressant) activities of Pindolol.]
[M03AC01, pancuronium, Pancuronium may increase the bradycardic activities of Pindolol.]
[J04AB30, capreomycin, Pindolol may decrease the excretion rate of Capreomycin which could result in a higher serum level.]
[G04BE02, papaverine, The risk or severity of adverse effects can be increased when Pindolol is combined with Papaverine.]
[N05CC05, paraldehyde, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Paraldehyde.]
[C02KC01, pargyline, Pargyline may increase the hypotensive activities of Pindolol.]
[A07AA06, paromomycin, Paromomycin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[G04BD11, fesoterodine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Fesoterodine.]
[C07AA23, penbutolol, The risk or severity of adverse effects can be increased when Pindolol is combined with Penbutolol.]
[N05AG03, penfluridol, The risk or severity of bradycardia can be increased when Penfluridol is combined with Pindolol.]
[J01CE09, penicillin G procaine, Pindolol may decrease the excretion rate of Procaine benzylpenicillin which could result in a higher serum level.]
[N02AD01, pentazocine, The risk or severity of adverse effects can be increased when Pentazocine is combined with Pindolol.]
[N05CA01, pentobarbital, Pentobarbital may increase the hypotensive activities of Pindolol.]
[L01XX08, pentostatin, Pindolol may decrease the excretion rate of Pentostatin which could result in a higher serum level.]
[C04AD03, pentoxifylline, Pentoxifylline may increase the hypotensive activities of Pindolol.]
[N05AB10, perazine, The serum concentration of Pindolol can be increased when it is combined with Perazine.]
[N04BC02, pergolide, The therapeutic efficacy of Pergolide can be decreased when used in combination with Pindolol.]
[C08EX02, perhexiline, The risk or severity of bradycardia can be increased when Perhexiline is combined with Pindolol.]
[N05AB03, perphenazine, The serum concentration of Pindolol can be increased when it is combined with Perphenazine.]
[N02BE03, phenacetin, The metabolism of Phenacetin can be decreased when combined with Pindolol.]
[N02AD02, phenazocine, The risk or severity of adverse effects can be increased when Pindolol is combined with Phenazocine.]
[G04BX06, phenazopyridine, Phenazopyridine may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N06AF03, phenelzine, Phenelzine may increase the hypotensive activities of Pindolol.]
[A10BA01, phenformin, The therapeutic efficacy of Phenformin can be increased when used in combination with Pindolol.]
[B01AA02, phenindione, The risk or severity of adverse effects can be increased when Pindolol is combined with Phenindione.]
[N03AA02, phenobarbital, Phenobarbital may increase the hypotensive activities of Pindolol.]
[N01AH04, phenoperidine, The risk or severity of adverse effects can be increased when Pindolol is combined with Phenoperidine.]
[C04AX02, phenoxybenzamine, Pindolol may increase the orthostatic hypotensive activities of Phenoxybenzamine.]
[B01AA04, phenprocoumon, The risk or severity of adverse effects can be increased when Pindolol is combined with Phenprocoumon.]
[A08AA01, phentermine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Phentermine.]
[V03AB36, phentolamine, Pindolol may increase the orthostatic hypotensive activities of Phentolamine.]
[M02AA01, phenylbutazone, Phenylbutazone may decrease the antihypertensive activities of Pindolol.]
[S01GA05, phenylephrine, The therapeutic efficacy of Phenylephrine can be decreased when used in combination with Pindolol.]
[R01BA01, phenylpropanolamine, Pindolol may decrease the bronchodilatory activities of Phenylpropanolamine.]
[N03AB02, phenytoin, The risk or severity of adverse effects can be increased when Phenytoin is combined with Pindolol.]
[L04AB06, golimumab, The metabolism of Pindolol can be increased when combined with Golimumab.]
[S01AE05, levofloxacin, Pindolol may decrease the excretion rate of Levofloxacin which could result in a higher serum level.]
[V03AB19, physostigmine, Physostigmine may increase the bradycardic activities of Pindolol.]
[B02BA01, vitamin K1, Pindolol may decrease the excretion rate of Phylloquinone which could result in a higher serum level.]
[J05AB12, cidofovir, Cidofovir may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C08CX01, mibefradil, The risk or severity of bradycardia can be increased when Mibefradil is combined with Pindolol.]
[S01EB01, pilocarpine, The risk or severity of adverse effects can be increased when Pindolol is combined with Pilocarpine.]
[N05AG02, pimozide, The metabolism of Pimozide can be decreased when combined with Pindolol.]
[N07XX04, sodium oxybate, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Sodium oxybate.]
[J01CA12, piperacillin, Piperacillin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J05AE01, saquinavir, The metabolism of Pindolol can be decreased when combined with Saquinavir.]
[P02CB01, piperazine, The metabolism of Piperazine can be decreased when combined with Pindolol.]
[N05AC04, pipothiazine, The serum concentration of Pindolol can be increased when it is combined with Pipotiazine.]
[N06BX03, piracetam, Pindolol may decrease the excretion rate of Piracetam which could result in a higher serum level.]
[C09CA02, eprosartan, Eprosartan may increase the hypotensive activities of Pindolol.]
[A02BX03, pirenzepine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Pirenzepine.]
[N02AC03, pirinitramide, The risk or severity of adverse effects can be increased when Pindolol is combined with Piritramide.]
[S01BC06, piroxicam, Piroxicam may decrease the antihypertensive activities of Pindolol.]
[J01DD16, cefditoren, Cefditoren may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[N02CX01, pizotyline, Pindolol may increase the orthostatic hypotensive activities of Pizotifen.]
[J05AG02, delavirdine, The metabolism of Pindolol can be decreased when combined with Delavirdine.]
[C09CA04, irbesartan, Pindolol may increase the hypotensive activities of Irbesartan.]
[N05CA22, proxibarbal, The risk or severity of adverse effects can be increased when Pindolol is combined with Proxibarbal.]
[A10BG02, rosiglitazone, The therapeutic efficacy of Rosiglitazone can be increased when used in combination with Pindolol.]
[A03AE01, alosetron, The risk or severity of adverse effects can be increased when Pindolol is combined with Alosetron.]
[L04AC08, canakinumab, The metabolism of Pindolol can be increased when combined with Canakinumab.]
[C03AA05, polythiazide, The therapeutic efficacy of Pindolol can be increased when used in combination with Polythiazide.]
[J05AE03, ritonavir, The metabolism of Pindolol can be decreased when combined with Ritonavir.]
[A10BH03, saxagliptin, The therapeutic efficacy of Saxagliptin can be increased when used in combination with Pindolol.]
[B05XA01, potassium chloride, Potassium chloride may increase the hyperkalemic activities of Pindolol.]
[V03AB21, potassium iodide, Potassium Iodide may increase the hyperkalemic activities of Pindolol.]
[A10AD04, insulin lispro, The therapeutic efficacy of Insulin lispro can be increased when used in combination with Pindolol.]
[C07AB01, practolol, Pindolol may increase the hypotensive activities of Practolol.]
[N05BA11, prazepam, The risk or severity of adverse effects can be increased when Pindolol is combined with Prazepam.]
[C02CA01, prazosin, The risk or severity of hypotension can be increased when Prazosin is combined with Pindolol.]
[H02AB07, prednisone, Prednisone may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[C01DX02, prenylamine, The risk or severity of bradycardia can be increased when Prenylamine is combined with Pindolol.]
[N01BB04, prilocaine, The risk or severity of adverse effects can be increased when Prilocaine is combined with Pindolol.]
[P01BA03, primaquine, The metabolism of Pindolol can be decreased when combined with Primaquine.]
[N03AA03, primidone, Primidone may increase the hypotensive activities of Pindolol.]
[M04AB01, probenecid, Pindolol may decrease the excretion rate of Probenecid which could result in a higher serum level.]
[C01BA02, procainamide, The metabolism of Procainamide can be decreased when combined with Pindolol.]
[S01HA05, procaine, Procaine may increase the bradycardic activities of Pindolol.]
[L01XB01, procarbazine, Procarbazine may increase the hypotensive activities of Pindolol.]
[C10AB05, fenofibrate, Pindolol may decrease the excretion rate of Fenofibrate which could result in a higher serum level.]
[N05AB04, prochlorperazine, The serum concentration of Pindolol can be increased when it is combined with Prochlorperazine.]
[N04AA04, procyclidine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Procyclidine.]
[G03DA04, progesterone, The metabolism of Progesterone can be decreased when combined with Pindolol.]
[N05AA03, promazine, The serum concentration of Pindolol can be increased when it is combined with Promazine.]
[R06AD02, promethazine, The serum concentration of Pindolol can be increased when it is combined with Promethazine.]
[C01BC03, propafenone, The risk or severity of adverse effects can be increased when Propafenone is combined with Pindolol.]
[N01AX04, propanidid, The risk or severity of adverse effects can be increased when Pindolol is combined with Propanidid.]
[A03AB05, propantheline, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Propantheline.]
[N05AC01, periciazine, The serum concentration of Pindolol can be increased when it is combined with Periciazine.]
[N05CM06, propiomazine, Pindolol may increase the orthostatic hypotensive activities of Propiomazine.]
[N01AX10, propofol, The risk or severity of adverse effects can be increased when Propofol is combined with Pindolol.]
[N02AC04, propoxyphene, The risk or severity of adverse effects can be increased when Dextropropoxyphene is combined with Pindolol.]
[C07AA05, propranolol, Propranolol may increase the hypotensive activities of Pindolol.]
[C01AB01, proscillaridin, Pindolol may increase the bradycardic activities of Proscillaridin.]
[N02CC04, rizatriptan, The risk or severity of adverse effects can be increased when Rizatriptan is combined with Pindolol.]
[B01AC09, epoprostenol, Epoprostenol may increase the hypotensive activities of Pindolol.]
[N06AA11, protriptyline, The risk or severity of adverse effects can be increased when Protriptyline is combined with Pindolol.]
[R01BA02, pseudoephedrine, The therapeutic efficacy of Pindolol can be decreased when used in combination with Pseudoephedrine.]
[N05AX12, aripiprazole, The risk or severity of hypotension can be increased when Aripiprazole is combined with Pindolol.]
[N07XX07, dalfampridine, Pindolol may decrease the excretion rate of Dalfampridine which could result in a higher serum level.]
[A03AB15, diphemanil, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Diphemanil.]
[A03AB09, isopropamide, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Isopropamide.]
[S01FA03, methscopolamine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Methscopolamine.]
[N05CA07, talbutal, The risk or severity of adverse effects can be increased when Talbutal is combined with Pindolol.]
[N05CA09, vinbarbital, The risk or severity of adverse effects can be increased when Pindolol is combined with Vinbarbital.]
[N05BB02, captodiamine, The risk or severity of adverse effects can be increased when Pindolol is combined with Captodiame.]
[M03BA04, styramate, The risk or severity of adverse effects can be increased when Pindolol is combined with Styramate.]
[P02CC01, pyrantel, The risk or severity of adverse effects can be increased when Pindolol is combined with Pyrantel.]
[J04AK01, pyrazinamide, Pyrazinamide may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[A12BA05, potassium gluconate, Potassium gluconate may increase the hyperkalemic activities of Pindolol.]
[N07AA02, pyridostigmine, Pyridostigmine may increase the bradycardic activities of Pindolol.]
[R06AC01, pyrilamine, The risk or severity of adverse effects can be increased when Pindolol is combined with Mepyramine.]
[C01BA01, quinidine, The metabolism of Pindolol can be decreased when combined with Quinidine.]
[P01BC01, quinine, The metabolism of Pindolol can be decreased when combined with Quinine.]
[A02BA02, ranitidine, The metabolism of Pindolol can be decreased when combined with Ranitidine.]
[C02AA01, rescinnamine, Rescinnamine may decrease the antihypertensive activities of Pindolol.]
[C02AA02, reserpine, Reserpine may increase the hypotensive activities of Pindolol.]
[J05AP01, ribavirin, Ribavirin may decrease the excretion rate of Pindolol which could result in a higher serum level.]
[J04AB02, rifampin, The metabolism of Pindolol can be increased when combined with Rifampicin.]
[R03AC05, rimiterol, The therapeutic efficacy of Rimiterol can be decreased when used in combination with Pindolol.]
[G02CA01, ritodrine, Pindolol may decrease the bronchodilatory activities of Ritodrine.]
[N06AX01, 5-hydroxytryptophan, The risk or severity of adverse effects can be increased when Pindolol is combined with Oxitriptan.]
[N02BA05, salicylamide, Salicylamide may decrease the antihypertensive activities of Pindolol.]
[A07EC01, sulfasalazine, Sulfasalazine may decrease the antihypertensive activities of Pindolol.]
[S01BC08, salicylic acid, Salicylic acid may decrease the antihypertensive activities of Pindolol.]
[S01FA02, scopolamine, Pindolol may increase the central nervous system depressant (CNS depressant) activities of Scopolamine.]
[N05CA06, secobarbital, Secobarbital may increase the hypotensive activities of Pindolol.]
[N04BD01, selegiline, Selegiline may increase the hypotensive activities of Pindolol.]
[L01FA03, obinutuzumab, Pindolol may increase the hypotensive activities of Obinutuzumab.]
[J01GB08, sisomicin, Pindolol may decrease the excretion rate of Sisomicin which could result in a higher serum level.]
[A12CD01, sodium fluoride, Pindolol may decrease the excretion rate of Sodium fluoride which could result in a higher serum level.]
[V04CC01, sorbitol, Pindolol may decrease the excretion rate of Sorbitol which could result in a higher serum level.]
[C07AA07, sotalol, The metabolism of Sotalol can be decreased when combined with Pindolol.]
[C03DA01, spironolactone, Spironolactone may increase the excretion rate of Pindolol which could result in a lower serum level and potentially a reduction in efficacy.]
